Age-Related Macular Degeneration (AMD) — RepurpOS

Disease overview

Alterations

153

Molecular (A)

Clinical (B–E)

Direct drugs

131

Via biomarker

322

Natural agents

Natural products

127

Merged ranked

450

With trial/literature evidence

Sources: Seeds, Open Targets, HPO, ClinicalTrials.gov, ChEMBL, DGIdb, PubMed MeSH, PubMed Literature · Pipeline phase 7 · Updated 2026-07-05

Remission & chronicity

Spontaneous remission

Dry AMD: slow progressive loss; wet AMD progresses rapidly without treatment (50% of untreated reach legal blindness within 2 years); no spontaneous remission of either form

Best-intervention remission

Anti-VEGF (ranibizumab, aflibercept, bevacizumab): 30-40% vision gain in wet AMD (MARINA, ANCHOR trials); maintain vision in 90%+ vs 62% in placebo; high-dose vitamin supplementation (AREDS2): 25% reduction in progression from intermediate to advanced dry AMD; port delivery system (Susvimo): 6-monthly refillable implant equivalent to monthly injections

Drug-free remission

—

Relapse after remission

—

Chronicity

—

Gap size

Large — treatment burden (monthly injections) is the primary barrier to adequate treatment in wet AMD; dry AMD has no proven disease-modifying treatment until 2023

Primary barrier

access/biological

Barrier detail: Monthly anti-VEGF injection burden leads to under-treatment in real-world settings; 50% of wet AMD patients in routine care lose vision compared to 5-10% in trials; geographic atrophy (dry AMD) had no approved treatment until pegcetacoplan (Syfovre, 2023)

Last SoC change: 2023 — pegcetacoplan (Syfovre, complement C3 inhibitor) and avacincaptad pegol (Izervay, complement C5 inhibitor) approved for geographic atrophy — first ever treatments for dry AMD; ranibizumab port delivery system (Susvimo) approved 2021; anti-VEGF since 2006

Remission data layers: disease_db_100 · source-locked manual data · confidence: high

Identifiers: MONDO: MONDO:0001208 · EFO: EFO_0001369 · ORPHA: ORPHA:391 · MESH: D008268 · UMLS_CUI: C0242383

Right to Try Relevance

Eligibility: This disease meets the federal and state right-to-try legal standard (21 U.S.C. § 360bbb-0a and Montana SB 535): it lacks disease-modifying therapy with indication-specific FDA approval. Patients with Age-Related Macular Degeneration may be eligible to access investigational therapies outside of clinical trials under right-to-try frameworks.

Investigational Agents

142

Phase 3: 43, Phase 2: 84, Phase 1: 15

Most Advanced Phase

Phase 3

Highest dev. stage

Gene Targets

153

Actionable

Pipeline Compounds (Top 6)

Darapladib, Fenretinide, Dexamethasone, Prednisolone, Triamcinolone, Triamcinolone Acetonide

Legal Standard: Right-to-try requires the disease lacks "adequate approved therapy for that specific disease" (not symptom-management drugs). This distinction means a disease with antidepressants available still qualifies if no FDA approval exists for THAT disease indication.

View Right-to-Try Compendium

Alterations

153 total · Types A (molecular) through E (functional)

Name	Type	Subtype	Direction	Frequency	Evidence	Sources	Links
Abnormal blood gas level	Lab / Clinical	Lab value	—	—	Moderate	HPO, Monarch	HPO
Abnormal circulating interleukin concentration	Lab / Clinical	Lab value	—	—	Moderate	HPO, Monarch	HPO
Abnormal sputum	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Abnormal thorax morphology	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Abnormality of tumor necrosis factor secretion	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Adult onset	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Anorexia	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Atelectasis	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Bradycardia	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Cardiac arrest	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Chest pain	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Cough	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Crackles	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Cyanosis	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Diabetic ketoacidosis	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Disseminated intravascular coagulation	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Dyspnea	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Edema	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Exercise intolerance	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Fever	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Headache	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Hemoptysis	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Hypotension	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Hypoxemia	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Increased circulating interleukin 6 concentration	Lab / Clinical	Lab value	—	—	Moderate	HPO, Monarch	HPO
Increased total leukocyte count	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Infantile onset	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Metabolic acidosis	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Nasal flaring	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Nausea and vomiting	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Neonatal onset	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Neonatal respiratory distress	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Orthopnea	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Pancreatitis	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Pediatric onset	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Pneumonia	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Premature birth	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Pulmonary edema	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Pulmonary infiltrates	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Pulmonary opacity	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Respiratory distress	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Respiratory failure	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Respiratory insufficiency	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Respiratory tract infection	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Sepsis	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Shock	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Sleep disturbance	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Tachycardia	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Tachypnea	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Vasculitis	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Vertigo	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
ABCA3 ATP binding cassette subfamily A member 3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ABL1 ABL proto-oncogene 1, non-receptor tyrosine kinase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ADRA1A adrenoceptor alpha 1A	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ADRA1B adrenoceptor alpha 1B	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ADRA1D adrenoceptor alpha 1D	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ADRA2A adrenoceptor alpha 2A	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ADRA2B adrenoceptor alpha 2B	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ADRA2C adrenoceptor alpha 2C	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ADRB1 adrenoceptor beta 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ADRB2 adrenoceptor beta 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
BCR BCR activator of RhoGEF and GTPase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
Best corrected visual acuity	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
C5 complement C5	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CSF2RA colony stimulating factor 2 receptor subunit alpha	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CSF2RB colony stimulating factor 2 receptor subunit beta	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
Change From Baseline in Plasma Amyloid (A) Beta (1-40) Concentration at Day 1, 2, 7, 14, 19, 28, 45, 56, 75, 84, 103, 112, 131, 140, 141, 154, 168, 224, 304/ET	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
FAAH fatty acid amide hydrolase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GABRA1 gamma-aminobutyric acid type A receptor subunit alpha1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GABRA2 gamma-aminobutyric acid type A receptor subunit alpha2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GABRA3 gamma-aminobutyric acid type A receptor subunit alpha3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GABRA4 gamma-aminobutyric acid type A receptor subunit alpha4	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GABRA5 gamma-aminobutyric acid type A receptor subunit alpha5	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GABRA6 gamma-aminobutyric acid type A receptor subunit alpha6	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GABRB1 gamma-aminobutyric acid type A receptor subunit beta1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GABRB2 gamma-aminobutyric acid type A receptor subunit beta2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GABRB3 gamma-aminobutyric acid type A receptor subunit beta3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GABRD gamma-aminobutyric acid type A receptor subunit delta	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GABRE gamma-aminobutyric acid type A receptor subunit epsilon	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GABRG1 gamma-aminobutyric acid type A receptor subunit gamma1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GABRG2 gamma-aminobutyric acid type A receptor subunit gamma2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GABRG3 gamma-aminobutyric acid type A receptor subunit gamma3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GABRP gamma-aminobutyric acid type A receptor subunit pi	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GABRQ gamma-aminobutyric acid type A receptor subunit theta	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GLRA1 glycine receptor alpha 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GLRB glycine receptor beta	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GRIN1 glutamate ionotropic receptor NMDA type subunit 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GRIN2A glutamate ionotropic receptor NMDA type subunit 2A	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GRIN2B glutamate ionotropic receptor NMDA type subunit 2B	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GRIN2C glutamate ionotropic receptor NMDA type subunit 2C	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GRIN2D glutamate ionotropic receptor NMDA type subunit 2D	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GRIN3A glutamate ionotropic receptor NMDA type subunit 3A	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GRIN3B glutamate ionotropic receptor NMDA type subunit 3B	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GUCY1A1 guanylate cyclase 1 soluble subunit alpha 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GUCY1A2 guanylate cyclase 1 soluble subunit alpha 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GUCY1B1 guanylate cyclase 1 soluble subunit beta 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
IGF1R insulin like growth factor 1 receptor	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
IL2RB interleukin 2 receptor subunit beta	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
IL2RG interleukin 2 receptor subunit gamma	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
IL6 interleukin 6	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
IL6R interleukin 6 receptor	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
JAK1 Janus kinase 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
JAK2 Janus kinase 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
JAK3 Janus kinase 3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
KCNK10 potassium two pore domain channel subfamily K member 10	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
KCNK18 potassium two pore domain channel subfamily K member 18	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
KCNK2 potassium two pore domain channel subfamily K member 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
KCNK3 potassium two pore domain channel subfamily K member 3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
KCNK9 potassium two pore domain channel subfamily K member 9	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
KIT KIT proto-oncogene, receptor tyrosine kinase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
MYRIP myosin VIIA and Rab interacting protein	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NKX2-1 NK2 homeobox 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NR3C1 nuclear receptor subfamily 3 group C member 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NR3C2 nuclear receptor subfamily 3 group C member 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PDE3A phosphodiesterase 3A	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PDE3B phosphodiesterase 3B	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PDGFRB platelet derived growth factor receptor beta	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PIK3R1 phosphoinositide-3-kinase regulatory subunit 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PLAT plasminogen activator, tissue type	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PLG plasminogen	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PPIA peptidylprolyl isomerase A	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PTGIR prostaglandin I2 receptor	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PTGS1 prostaglandin-endoperoxide synthase 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PTGS2 prostaglandin-endoperoxide synthase 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
Percent Change From Baseline in Plasma Amyloid (A) Beta (1-40) Concentrations at Day 1, 2, 7, 14, 19, 28, 45, 56, 75, 84, 103, 112, 131, 140, 141, 154, 168, 224, 304/ET	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
SCN4A sodium voltage-gated channel alpha subunit 4	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
SCN5A sodium voltage-gated channel alpha subunit 5	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
SERPINC1 serpin family C member 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
SFTPA2 surfactant protein A2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
SFTPB surfactant protein B	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
SFTPC surfactant protein C	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
SLC12A1 solute carrier family 12 member 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TNNC1 troponin C1, slow skeletal and cardiac type	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TNNI3 troponin I3, cardiac type	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TNNT2 troponin T2, cardiac type	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TRPV1 transient receptor potential cation channel subfamily V member 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TUBA1A tubulin alpha 1a	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TUBA1B tubulin alpha 1b	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TUBA1C tubulin alpha 1c	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TUBA3C tubulin alpha 3c	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TUBA3E tubulin alpha 3e	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TUBA4A tubulin alpha 4a	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TUBB tubulin beta class I	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TUBB1 tubulin beta 1 class VI	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TUBB2A tubulin beta 2A class IIa	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TUBB2B tubulin beta 2B class IIb	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TUBB3 tubulin beta 3 class III	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TUBB4A tubulin beta 4A class IVa	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TUBB4B tubulin beta 4B class IVb	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TUBB6 tubulin beta 6 class V	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TUBB8 tubulin beta 8 class VIII	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TYK2 tyrosine kinase 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
VEGFA vascular endothelial growth factor A	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets

FDA-Approved Therapies

Phase 4 agents with regulatory approval for this indication

Drug Name	Mechanism	Type
ACEBUTOLOL	inhibitor	Gene-targeted
ACEBUTOLOL HYDROCHLORIDE	inhibitor	Gene-targeted
ACETAZOLAMIDE	None	Gene-targeted
ACYCLOVIR		Gene-targeted
ADENOSINE TRIPHOSPHATE		Gene-targeted
ALBUTEROL SULFATE	agonist	Gene-targeted
ALFUZOSIN	inhibitor	Gene-targeted
ALFUZOSIN HYDROCHLORIDE	agonist	Gene-targeted
AMIODARONE HYDROCHLORIDE		Gene-targeted
AMITRIPTYLINE HYDROCHLORIDE	inhibitor	Gene-targeted
AMPHETAMINE	None	Gene-targeted
APOMORPHINE	inhibitor	Gene-targeted
APRACLONIDINE	agonist	Gene-targeted
APRACLONIDINE HYDROCHLORIDE	agonist	Gene-targeted
ARBUTAMINE		Gene-targeted
ARFORMOTEROL		Gene-targeted
ARFORMOTEROL TARTRATE	agonist	Gene-targeted
ASCIMINIB	modulator; inhibitor	Gene-targeted
ASCIMINIB HYDROCHLORIDE	inhibitor	Gene-targeted
ASENAPINE		Gene-targeted
ATENOLOL	inhibitor	Gene-targeted
ATIPAMEZOLE	inhibitor	Gene-targeted
ATROPINE	inhibitor	Gene-targeted
AXITINIB		Gene-targeted
AZACITIDINE		Gene-targeted
BENZPHETAMINE		Gene-targeted
BETAXOLOL	inhibitor	Gene-targeted
BETAXOLOL HYDROCHLORIDE	inhibitor	Gene-targeted
BETHANIDINE		Gene-targeted
BICALUTAMIDE	None	Gene-targeted
BISOPROLOL	inhibitor	Gene-targeted
BISOPROLOL FUMARATE	inhibitor	Gene-targeted
BITOLTEROL MESYLATE	agonist	Gene-targeted
BLINATUMOMAB		Gene-targeted
BOSUTINIB	inhibitor; inhibitor	Gene-targeted
BOSUTINIB MONOHYDRATE	inhibitor	Gene-targeted
BRETYLIUM		Gene-targeted
BRIMONIDINE	agonist	Gene-targeted
BRIMONIDINE TARTRATE	agonist	Gene-targeted
BROMOCRIPTINE	inhibitor	Gene-targeted
BUSULFAN		Gene-targeted
CABERGOLINE	inhibitor	Gene-targeted
CABOZANTINIB S-MALATE		Gene-targeted
CARBACHOL	None	Gene-targeted
CARTEOLOL		Gene-targeted
CARTEOLOL HYDROCHLORIDE	inhibitor	Gene-targeted
CARVEDILOL	inhibitor; inhibitor	Gene-targeted
CARVEDILOL PHOSPHATE	inhibitor	Gene-targeted
CELECOXIB		Gene-targeted
CELIPROLOL	inhibitor	Gene-targeted
CHEMBL5314346	None	Direct
CHLORPROMAZINE	inhibitor	Gene-targeted
CIPROFLOXACIN	None	Gene-targeted
CLOMIPRAMINE	inhibitor	Gene-targeted
CLOMIPRAMINE	None	Gene-targeted
CLONIDINE HYDROCHLORIDE	agonist; agonist	Gene-targeted
CLOTRIMAZOLE		Gene-targeted
CLOZAPINE	inhibitor	Gene-targeted
CRIZOTINIB		Gene-targeted
CYCLOBENZAPRINE		Gene-targeted
CYPROHEPTADINE HYDROCHLORIDE	inhibitor	Gene-targeted
DAPIPRAZOLE	inhibitor	Gene-targeted
DAPIPRAZOLE HYDROCHLORIDE	inhibitor	Gene-targeted
DASATINIB ANHYDROUS	inhibitor; inhibitor	Gene-targeted
DEBRISOQUIN		Gene-targeted
DESIPRAMINE		Gene-targeted
DEXMEDETOMIDINE HYDROCHLORIDE	agonist	Gene-targeted
DEXTROAMPHETAMINE SULFATE		Gene-targeted
DIAZEPAM	None	Gene-targeted
DICHLORPHENAMIDE	None	Gene-targeted
DIENESTROL		Gene-targeted
DIETHYLSTILBESTROL	None	Gene-targeted
DILEVALOL HYDROCHLORIDE	inhibitor; agonist	Gene-targeted
DIPIVEFRIN		Gene-targeted
DIPIVEFRIN HYDROCHLORIDE	agonist	Gene-targeted
DISULFIRAM		Gene-targeted
DOBUTAMINE	agonist	Gene-targeted
DOBUTAMINE HYDROCHLORIDE	agonist	Gene-targeted
DOPAMINE		Gene-targeted
DOPAMINE HYDROCHLORIDE	agonist	Gene-targeted
DOXAZOSIN MESYLATE	inhibitor	Gene-targeted
DOXAZOSIN MESYLATE	inhibitor	Gene-targeted
DRONEDARONE		Gene-targeted
DROXIDOPA	agonist	Gene-targeted
ENALAPRIL MALEATE		Gene-targeted
ENTRECTINIB		Gene-targeted
EPHEDRINE	agonist	Gene-targeted
EPHEDRINE HYDROCHLORIDE	agonist	Gene-targeted
EPHEDRINE SULFATE	agonist	Gene-targeted
EPINEPHRINE	agonist; agonist	Gene-targeted
EPINEPHRINE BITARTRATE	agonist	Gene-targeted
EPIRUBICIN	None	Gene-targeted
ERGOLOID MESYLATES	inhibitor	Gene-targeted
ERGOLOID MESYLATES, USP		Gene-targeted
ERGOTAMINE		Gene-targeted
ERGOTAMINE TARTRATE	agonist	Gene-targeted
ERLOTINIB		Gene-targeted
ESMOLOL	inhibitor	Gene-targeted
ESMOLOL HYDROCHLORIDE	inhibitor	Gene-targeted
ETHOXZOLAMIDE	None	Gene-targeted
ETOMIDATE		Gene-targeted
FENOLDOPAM		Gene-targeted
FENOTEROL	agonist; agonist	Gene-targeted
FLECAINIDE ACETATE		Gene-targeted
FLUMAZENIL	None	Gene-targeted
FORMOTEROL FUMARATE	agonist	Gene-targeted
FORMOTEROL FUMARATE	agonist	Gene-targeted
FOSLEVODOPA	agonist	Gene-targeted
GENISTEIN		Gene-targeted
GLYCOPYRRONIUM BROMIDE		Gene-targeted
GUANABENZ	agonist	Gene-targeted
GUANABENZ ACETATE	agonist	Gene-targeted
GUANFACINE HYDROCHLORIDE	agonist	Gene-targeted
GUANFACINE HYDROCHLORIDE	agonist	Gene-targeted
HYDROXYAMPHETAMINE HYDROBROMIDE	agonist	Gene-targeted
HYDROXYUREA		Gene-targeted
ILOPERIDONE		Gene-targeted
IMATINIB	inhibitor; inhibitor	Gene-targeted
IMATINIB MESYLATE	inhibitor	Gene-targeted
IMIPRAMINE	None	Gene-targeted
INDACATEROL	agonist	Gene-targeted
INDACATEROL MALEATE	agonist	Gene-targeted
INDAPAMIDE	None	Gene-targeted
INDOMETHACIN	None	Gene-targeted
INOTUZUMAB OZOGAMICIN		Gene-targeted
ISOETHARINE		Gene-targeted
ISOETHARINE HYDROCHLORIDE	agonist	Gene-targeted
ISOETHARINE MESYLATE	agonist	Gene-targeted
ISOPROTERENOL	agonist	Gene-targeted
ISOPROTERENOL HYDROCHLORIDE	agonist	Gene-targeted
ISOPROTERENOL SULFATE	agonist	Gene-targeted
ISOSORBIDE DINITRATE	None	Gene-targeted
LABETALOL	inhibitor	Gene-targeted
LABETALOL HYDROCHLORIDE	inhibitor	Gene-targeted
LANDIOLOL	inhibitor; inhibitor	Gene-targeted
LANDIOLOL HYDROCHLORIDE	inhibitor	Gene-targeted
LEVALBUTEROL		Gene-targeted
LEVALBUTEROL HYDROCHLORIDE	agonist	Gene-targeted
LEVALBUTEROL TARTRATE	agonist	Gene-targeted
LEVOBETAXOLOL HYDROCHLORIDE	inhibitor	Gene-targeted
LEVOBUNOLOL	inhibitor	Gene-targeted
LEVOBUNOLOL HYDROCHLORIDE	inhibitor	Gene-targeted
LEVONORDEFRIN	agonist	Gene-targeted
LISDEXAMFETAMINE DIMESYLATE		Gene-targeted
LOFEXIDINE	agonist	Gene-targeted
LOFEXIDINE HYDROCHLORIDE	agonist	Gene-targeted
LURASIDONE HYDROCHLORIDE	inhibitor	Gene-targeted
MAFENIDE	None	Gene-targeted
MECAMYLAMINE	None	Gene-targeted
MELPHALAN		Gene-targeted
MEPERIDINE HYDROCHLORIDE		Gene-targeted
MEPHENTERMINE		Gene-targeted
MEPHENTERMINE SULFATE	agonist	Gene-targeted
MEPOLIZUMAB		Gene-targeted
METAPROTERENOL	agonist	Gene-targeted
METAPROTERENOL SULFATE		Gene-targeted
METARAMINOL		Gene-targeted
METARAMINOL BITARTRATE	agonist	Gene-targeted
METHACHOLINE		Gene-targeted
METHAMPHETAMINE		Gene-targeted
METHAZOLAMIDE	None	Gene-targeted
METHOTRIMEPRAZINE		Gene-targeted
METHOXAMINE	agonist	Gene-targeted
METHOXAMINE HYDROCHLORIDE	agonist	Gene-targeted
METHOXSALEN	None	Gene-targeted
METHYLDOPA ANHYDROUS	agonist	Gene-targeted
METHYLDOPATE HYDROCHLORIDE	agonist	Gene-targeted
METIPRANOLOL		Gene-targeted
METIPRANOLOL HYDROCHLORIDE	inhibitor	Gene-targeted
METOPROLOL	inhibitor	Gene-targeted
METOPROLOL	None	Gene-targeted
METOPROLOL FUMARATE	inhibitor	Gene-targeted
METOPROLOL SUCCINATE		Gene-targeted
METOPROLOL SUCCINATE	inhibitor	Gene-targeted
METOPROLOL TARTRATE	inhibitor	Gene-targeted
MIANSERIN	None	Gene-targeted
MIDODRINE		Gene-targeted
MIDODRINE HYDROCHLORIDE	agonist	Gene-targeted
MILNACIPRAN		Gene-targeted
MIRABEGRON	agonist	Gene-targeted
MIRTAZAPINE	inhibitor; inhibitor	Gene-targeted
MODAFINIL		Gene-targeted
MOXISYLYTE	inhibitor	Gene-targeted
MOXONIDINE	agonist	Gene-targeted
NADOLOL	inhibitor	Gene-targeted
NADOLOL	inhibitor	Gene-targeted
NAFTOPIDIL	inhibitor	Gene-targeted
NALIDIXIC ACID	None	Gene-targeted
NAPHAZOLINE	agonist	Gene-targeted
NAPHAZOLINE HYDROCHLORIDE	agonist	Gene-targeted
NEBIVOLOL HYDROCHLORIDE		Gene-targeted
NEBIVOLOL HYDROCHLORIDE	inhibitor	Gene-targeted
NEFAZODONE		Gene-targeted
NICOTINE	None	Gene-targeted
NIFEDIPINE		Gene-targeted
NILOTINIB	inhibitor; inhibitor	Gene-targeted
NILOTINIB HYDROCHLORIDE MONOHYDRATE	inhibitor	Gene-targeted
NOREPINEPHRINE	agonist	Gene-targeted
NOREPINEPHRINE BITARTRATE	agonist	Gene-targeted
NORFLOXACIN	None	Gene-targeted
NORTRIPTYLINE	inhibitor	Gene-targeted
OFLOXACIN	None	Gene-targeted
OLANZAPINE		Gene-targeted
OLODATEROL	agonist	Gene-targeted
OLODATEROL HYDROCHLORIDE	agonist	Gene-targeted
OMACETAXINE		Gene-targeted
OMACETAXINE MEPESUCCINATE		Gene-targeted
OXALIPLATIN		Gene-targeted
OXPRENOLOL		Gene-targeted
OXPRENOLOL HYDROCHLORIDE	inhibitor	Gene-targeted
OXYMETAZOLINE HYDROCHLORIDE	agonist	Gene-targeted
OXYMETAZOLINE HYDROCHLORIDE	agonist	Gene-targeted
PAPAVERINE		Gene-targeted
PAZOPANIB		Gene-targeted
PENBUTOLOL		Gene-targeted
PENBUTOLOL SULFATE	inhibitor	Gene-targeted
PERGOLIDE	agonist	Gene-targeted
PHENDIMETRAZINE		Gene-targeted
PHENOXYBENZAMINE	inhibitor	Gene-targeted
PHENOXYBENZAMINE HYDROCHLORIDE	inhibitor	Gene-targeted
PHENTOLAMINE	inhibitor	Gene-targeted
PHENTOLAMINE MESYLATE	inhibitor	Gene-targeted
PHENYLEPHRINE	agonist	Gene-targeted
PHENYLEPHRINE BITARTRATE	agonist	Gene-targeted
PHENYLEPHRINE HYDROCHLORIDE	agonist	Gene-targeted
PHENYLPROPANOLAMINE		Gene-targeted
PHENYLPROPANOLAMINE HYDROCHLORIDE	agonist	Gene-targeted
PHENYLPROPANOLAMINE POLISTIREX	agonist	Gene-targeted
PHENYTOIN	None	Gene-targeted
PINDOLOL	agonist; inhibitor; agonist	Gene-targeted
PIRBUTEROL		Gene-targeted
PIRBUTEROL ACETATE	agonist	Gene-targeted
PONATINIB	inhibitor; inhibitor	Gene-targeted
PONATINIB HYDROCHLORIDE	inhibitor	Gene-targeted
PRACTOLOL	inhibitor; inhibitor	Gene-targeted
PRAZOSIN	inhibitor	Gene-targeted
PRAZOSIN	None	Gene-targeted
PRAZOSIN HYDROCHLORIDE	inhibitor	Gene-targeted
PRILOCAINE HYDROCHLORIDE		Gene-targeted
PROGESTERONE		Gene-targeted
PROMAZINE		Gene-targeted
PRONETALOL	inhibitor	Gene-targeted
PROPAFENONE	inhibitor	Gene-targeted
PROPAFENONE HYDROCHLORIDE	inhibitor	Gene-targeted
PROPIOMAZINE		Gene-targeted
PROPRANOLOL HYDROCHLORIDE		Gene-targeted
PROPRANOLOL HYDROCHLORIDE	inhibitor	Gene-targeted
PROPYLHEXEDRINE		Gene-targeted
PROTOKYLOL HYDROCHLORIDE	agonist	Gene-targeted
PSEUDOEPHEDRINE POLISTIREX		Gene-targeted
QUETIAPINE FUMARATE		Gene-targeted
RACEPINEPHRINE	agonist	Gene-targeted
RAMIPRIL		Gene-targeted
RAUWOLFIA SERPENTINA	inhibitor	Gene-targeted
RAUWOLFIA SERPENTINA (USP)	inhibitor	Gene-targeted
REGORAFENIB	inhibitor	Gene-targeted
REMIFENTANIL HYDROCHLORIDE		Gene-targeted
RILMENIDINE		Gene-targeted
RISPERIDONE	inhibitor	Gene-targeted
RITODRINE		Gene-targeted
RITODRINE HYDROCHLORIDE	agonist	Gene-targeted
SALMETEROL	agonist	Gene-targeted
SALMETEROL XINAFOATE	agonist	Gene-targeted
SERTINDOLE	inhibitor	Gene-targeted
SILODOSIN	inhibitor	Gene-targeted
SIROLIMUS	None	Gene-targeted
SODIUM CHLORIDE		Gene-targeted
SORAFENIB		Gene-targeted
SOTALOL	inhibitor	Gene-targeted
SOTALOL HYDROCHLORIDE	inhibitor	Gene-targeted
SUFENTANIL		Gene-targeted
SULBACTAM	None	Gene-targeted
TACROLIMUS ANHYDROUS	None	Gene-targeted
TAMSULOSIN HYDROCHLORIDE	inhibitor	Gene-targeted
TAMSULOSIN HYDROCHLORIDE	inhibitor	Gene-targeted
TAZOBACTAM	None	Gene-targeted
TERAZOSIN	inhibitor	Gene-targeted
TERAZOSIN HYDROCHLORIDE	inhibitor	Gene-targeted
TERBUTALINE	agonist	Gene-targeted
TERBUTALINE SULFATE	agonist	Gene-targeted
TETRAHYDROZOLINE		Gene-targeted
TETRAHYDROZOLINE HYDROCHLORIDE	agonist	Gene-targeted
THIORIDAZINE		Gene-targeted
TIMOLOL	inhibitor; inhibitor	Gene-targeted
TIMOLOL MALEATE	inhibitor	Gene-targeted
TIOTROPIUM		Gene-targeted
TIZANIDINE HYDROCHLORIDE	agonist	Gene-targeted
TIZANIDINE HYDROCHLORIDE	agonist	Gene-targeted
TOLAZOLINE	inhibitor	Gene-targeted
TOLAZOLINE HYDROCHLORIDE	inhibitor	Gene-targeted
TRAMETINIB DIMETHYL SULFOXIDE		Gene-targeted
TRAZODONE		Gene-targeted
TRIFLUOPERAZINE		Gene-targeted
TRIMIPRAMINE MALEATE	inhibitor	Gene-targeted
TROGLITAZONE	None	Gene-targeted
UMBRALISIB TOSYLATE	inhibitor	Gene-targeted
VANDETANIB		Gene-targeted
VENETOCLAX		Gene-targeted
VILANTEROL	agonist	Gene-targeted
VILANTEROL TRIFENATATE	agonist	Gene-targeted
VINCRISTINE		Gene-targeted
XYLAZINE	agonist	Gene-targeted
XYLOMETAZOLINE	agonist	Gene-targeted
XYLOMETAZOLINE HYDROCHLORIDE	agonist	Gene-targeted
YOHIMBINE	inhibitor	Gene-targeted
ZIPRASIDONE		Gene-targeted

Therapeutics

Direct disease associations, biomarker-linked drugs, OSMF narrative-review natural agents, and merged ranking. Only agents with registry trials or published clinical literature are shown by default.

Show agents without direct trial evidence

Drug	Type	Phase	Evidence	Score	Trials & literature	Sources	Links
CHEMBL5314346	Small molecule	Approved	Strong	100	No indexed hits View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL Open Targets
ACEBUTOLOL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ACEBUTOLOL HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
ACETAZOLAMIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ACYCLOVIR Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ADENOSINE TRIPHOSPHATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ALBUTEROL SULFATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
ALFUZOSIN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ALFUZOSIN HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
AMIODARONE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
AMITRIPTYLINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
AMPHETAMINE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
APOMORPHINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
APRACLONIDINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
APRACLONIDINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
ARBUTAMINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ARFORMOTEROL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ARFORMOTEROL TARTRATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
ASCIMINIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ASCIMINIB HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
ASENAPINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ATENOLOL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ATIPAMEZOLE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ATROPINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
AXITINIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
AZACITIDINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BENZPHETAMINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BETAXOLOL Repurposing	Small molecule	Approved	Strong	95	2 Trial pubs 2 RCT View evidence Published literature Clinical trial publication [Serum lipid profile in non-exudative AMD patients treated with locally administrated beta-blockers] (Klinika oczna, 2004) Clinical trial publication Randomized clinical trial of topical betaxolol for persistent macular edema after vitrectomy and epiretinal membrane removal (American journal of ophthalmology, 2003) CT.gov search · Cochrane · PubMed	DGIdb	—
BETAXOLOL HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
BETHANIDINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BICALUTAMIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
BISOPROLOL Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
BISOPROLOL FUMARATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
BITOLTEROL MESYLATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
BLINATUMOMAB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BOSUTINIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BOSUTINIB MONOHYDRATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
BRETYLIUM Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BRIMONIDINE Repurposing	Small molecule	Approved	Strong	95	4 trials 6 Trial pubs 5 RCT View evidence Registry trials NCT00864838 — Oral Acetazolamide, Brimonidine Tartarate, and Anterior Chamber Paracentesis for Ocular Hypertension Control After Intravitreal Bevacizumab (COMPLETED) PHASE2 NCT00804921 — Effectiveness of Oral Acetazolamide, Brimonidine Tartarate, and Anterior Chamber Paracentesis in Intraocular Pressure (IOP) After Bevacizumab (COMPLETED) PHASE2 NCT02087085 — A Safety and Efficacy Study of Brimonidine Intravitreal Implant in Geographic Atrophy Secondary to Age-related Macular Degeneration (TERMINATED) PHASE2 NCT00658619 — Safety and Efficacy of Brimonidine Intravitreal Implant in Patients With Geographic Atrophy Due to Age-related Macular Degeneration (AMD) (COMPLETED) PHASE2 Published literature Clinical trial publication Randomized Phase IIb Study of Brimonidine Drug Delivery System Generation 2 for Geographic Atrophy in Age-Related Macular Degeneration (Ophthalmology. Retina, 2023) Clinical trial publication PHASE 2 STUDY OF THE SAFETY AND EFFICACY OF BRIMONIDINE DRUG DELIVERY SYSTEM (BRIMO DDS) GENERATION 1 IN PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION (Retina (Philadelphia, Pa.), 2021) Clinical trial publication Hypotensive efficacy of topical brimonidine for intraocular pressure spikes following intravitreal injections of antivascular endothelial growth factor agents: a randomised crossover trial (The British journal of ophthalmology, 2019) Clinical trial publication Role of brimonidine in the treatment of clinically significant macular edema with ischemic changes in diabetic maculopathy (International ophthalmology, 2014) Clinical trial publication Comparison of dorzolamide/timolol versus brimonidine/timolol fixed combination therapy in the management of steroid-induced ocular hypertension (Journal of glaucoma, 2015) CT.gov search · Cochrane · PubMed	DGIdb	—
BRIMONIDINE TARTRATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
BROMOCRIPTINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BUSULFAN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CABERGOLINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CABOZANTINIB S-MALATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CARBACHOL Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
CARTEOLOL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CARTEOLOL HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
CARVEDILOL Repurposing	Small molecule	Approved	Strong	95	1 pubs View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
CARVEDILOL PHOSPHATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
CELECOXIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CELIPROLOL Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
CHEMBL267936	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL Open Targets
CHEMBL269732	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL Open Targets
CHEMBL413	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL Open Targets
CHLORPROMAZINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CIPROFLOXACIN Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
CLOMIPRAMINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CLOMIPRAMINE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
CLONIDINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
CLOTRIMAZOLE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CLOZAPINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CRIZOTINIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CYCLOBENZAPRINE Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
CYPROHEPTADINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
DAPIPRAZOLE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
DAPIPRAZOLE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
DASATINIB ANHYDROUS Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
DEBRISOQUIN Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
DESIPRAMINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
DEXMEDETOMIDINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
DEXTROAMPHETAMINE SULFATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
DIAZEPAM Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
DICHLORPHENAMIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
DIENESTROL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
DIETHYLSTILBESTROL Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
DILEVALOL HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
DIPIVEFRIN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
DIPIVEFRIN HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
DISULFIRAM Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
DOBUTAMINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
DOBUTAMINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
DOPAMINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
DOPAMINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
DOXAZOSIN MESYLATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
DOXAZOSIN MESYLATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
DRONEDARONE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
DROXIDOPA Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ENALAPRIL MALEATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ENTRECTINIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
EPHEDRINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
EPHEDRINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
EPHEDRINE SULFATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
EPINEPHRINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
EPINEPHRINE BITARTRATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
EPIRUBICIN Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ERGOLOID MESYLATES Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
ERGOLOID MESYLATES, USP Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ERGOTAMINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ERGOTAMINE TARTRATE Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	ChEMBL Open Targets
ERLOTINIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ESMOLOL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ESMOLOL HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
ETHOXZOLAMIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ETOMIDATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
FENOLDOPAM Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
FENOTEROL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
FLECAINIDE ACETATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
FLUMAZENIL Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
FORMOTEROL FUMARATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
FORMOTEROL FUMARATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
FOSLEVODOPA Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
GENISTEIN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
GLYCOPYRRONIUM BROMIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
GUANABENZ Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
GUANABENZ ACETATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
GUANFACINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
GUANFACINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
HYDROXYAMPHETAMINE HYDROBROMIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
HYDROXYUREA Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ILOPERIDONE Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
IMATINIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
IMATINIB MESYLATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
IMIPRAMINE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
INDACATEROL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
INDACATEROL MALEATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
INDAPAMIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
INDOMETHACIN Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
INOTUZUMAB OZOGAMICIN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ISOETHARINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ISOETHARINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
ISOETHARINE MESYLATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
ISOPROTERENOL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ISOPROTERENOL HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
ISOPROTERENOL SULFATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
ISOSORBIDE DINITRATE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
LABETALOL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
LABETALOL HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
LANDIOLOL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
LANDIOLOL HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
LEVALBUTEROL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
LEVALBUTEROL HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
LEVALBUTEROL TARTRATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
LEVOBETAXOLOL HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
LEVOBUNOLOL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
LEVOBUNOLOL HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
LEVONORDEFRIN Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
LISDEXAMFETAMINE DIMESYLATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
LOFEXIDINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
LOFEXIDINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	ChEMBL Open Targets
LURASIDONE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
MAFENIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
MELPHALAN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
MEPERIDINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
MEPHENTERMINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
MEPHENTERMINE SULFATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
MEPOLIZUMAB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
METAPROTERENOL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
METAPROTERENOL SULFATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
METARAMINOL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
METARAMINOL BITARTRATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
METHACHOLINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
METHAMPHETAMINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
METHAZOLAMIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
METHOTRIMEPRAZINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
METHOXAMINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
METHOXAMINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
METHOXSALEN Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
METHYLDOPA ANHYDROUS Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
METHYLDOPATE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
METIPRANOLOL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
METIPRANOLOL HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
METOPROLOL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
METOPROLOL Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
METOPROLOL FUMARATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
METOPROLOL SUCCINATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
METOPROLOL SUCCINATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
METOPROLOL TARTRATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
MIANSERIN Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
MIDODRINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
MIDODRINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
MILNACIPRAN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
MIRABEGRON Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
MIRTAZAPINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
MODAFINIL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
MOXISYLYTE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
MOXONIDINE Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
NADOLOL Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
NADOLOL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
NAFTOPIDIL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
NALIDIXIC ACID Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
NAPHAZOLINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
NAPHAZOLINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
NEBIVOLOL HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
NEBIVOLOL HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
NEFAZODONE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
NICOTINE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
NIFEDIPINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
NILOTINIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
NILOTINIB HYDROCHLORIDE MONOHYDRATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
NOREPINEPHRINE Repurposing	Small molecule	Approved	Strong	95	3 pubs View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
NOREPINEPHRINE BITARTRATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
NORFLOXACIN Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
NORTRIPTYLINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
OFLOXACIN Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
OLANZAPINE Repurposing	Small molecule	Approved	Strong	95	1 pubs View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
OLODATEROL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
OLODATEROL HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
OMACETAXINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
OMACETAXINE MEPESUCCINATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
OXALIPLATIN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
OXPRENOLOL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
OXPRENOLOL HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
OXYMETAZOLINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
OXYMETAZOLINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
PAPAVERINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
PAZOPANIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
PENBUTOLOL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
PENBUTOLOL SULFATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
PERGOLIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
PHENDIMETRAZINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
PHENOXYBENZAMINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
PHENOXYBENZAMINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
PHENTOLAMINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
PHENTOLAMINE MESYLATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
PHENYLEPHRINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
PHENYLEPHRINE BITARTRATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
PHENYLEPHRINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
PHENYLPROPANOLAMINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
PHENYLPROPANOLAMINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
PHENYLPROPANOLAMINE POLISTIREX Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
PHENYTOIN Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
PINDOLOL Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
PIRBUTEROL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
PIRBUTEROL ACETATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
PONATINIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
PONATINIB HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
PRACTOLOL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
PRAZOSIN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
PRAZOSIN Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
PRAZOSIN HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
PRILOCAINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
PROGESTERONE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
PROMAZINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
PRONETALOL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
PROPAFENONE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
PROPAFENONE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
PROPIOMAZINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
PROPRANOLOL HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	1 trials View evidence Registry trials NCT03609307 — Comparison of Treatment Response to Intravitreal Injection of Combined Propranolol and Bevacizumab Versus Bevacizumab Monotherapy in Patients With Wet Age Related Macular Degeneration :A Clinical Trial (UNKNOWN) PHASE2, PHASE3 CT.gov search · Cochrane · PubMed	DGIdb	—
PROPRANOLOL HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
PROPYLHEXEDRINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
PROTOKYLOL HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
PSEUDOEPHEDRINE POLISTIREX Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
QUETIAPINE FUMARATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
RACEPINEPHRINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
RAMIPRIL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
RAUWOLFIA SERPENTINA Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
RAUWOLFIA SERPENTINA (USP) Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
REGORAFENIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
REMIFENTANIL HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
RILMENIDINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
RISPERIDONE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
RITODRINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
RITODRINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
SALMETEROL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
SALMETEROL XINAFOATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
SERTINDOLE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
SILODOSIN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
SODIUM CHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
SORAFENIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
SOTALOL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
SOTALOL HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
SUFENTANIL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
SULBACTAM Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
TAMSULOSIN HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
TAMSULOSIN HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
TAZOBACTAM Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
TERAZOSIN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
TERAZOSIN HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
TERBUTALINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
TERBUTALINE SULFATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
TETRAHYDROZOLINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
TETRAHYDROZOLINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
THIORIDAZINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
TIMOLOL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
TIMOLOL MALEATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
TIOTROPIUM Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
TIZANIDINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
TIZANIDINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
TOLAZOLINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
TOLAZOLINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
TRAMETINIB DIMETHYL SULFOXIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
TRAZODONE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
TRIFLUOPERAZINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
TRIMIPRAMINE MALEATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
TROGLITAZONE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
UMBRALISIB TOSYLATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
VANDETANIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
VENETOCLAX Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
VILANTEROL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
VILANTEROL TRIFENATATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
VINCRISTINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
XYLAZINE Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
XYLOMETAZOLINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
XYLOMETAZOLINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
YOHIMBINE Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
ZIPRASIDONE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
DEXAMETHASONE	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
PREDNISOLONE	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
TRIAMCINOLONE	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
TRIAMCINOLONE ACETONIDE	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
ACETAMINOPHEN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ALMITRINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
AVIPTADIL	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CELECOXIB	Small molecule	Phase III	Moderate	80	—	Open Targets, ChEMBL	ChEMBL Open Targets
CHEMBL1201421	Small molecule	Phase III	Moderate	80	—	ChEMBL	ChEMBL Open Targets
CHEMBL1201583	Small molecule	Phase III	Moderate	80	—	ChEMBL	ChEMBL Open Targets
CHEMBL1201825	Small molecule	Phase III	Moderate	80	—	ChEMBL	ChEMBL Open Targets
CHEMBL1293	Small molecule	Phase III	Moderate	80	—	ChEMBL	ChEMBL Open Targets
CHEMBL1742982	Small molecule	Phase III	Moderate	80	—	ChEMBL	ChEMBL Open Targets
CHEMBL196	Small molecule	Phase III	Moderate	80	—	ChEMBL	ChEMBL Open Targets
CHEMBL2106613	Small molecule	Phase III	Moderate	80	—	ChEMBL	ChEMBL Open Targets
CHEMBL2108313	Small molecule	Phase III	Moderate	80	—	ChEMBL	ChEMBL Open Targets
CHEMBL2110581	Small molecule	Phase III	Moderate	80	—	ChEMBL	ChEMBL Open Targets
CHEMBL25	Small molecule	Phase III	Moderate	80	—	ChEMBL	ChEMBL Open Targets
CHEMBL3301576	Small molecule	Phase III	Moderate	80	—	ChEMBL	ChEMBL Open Targets
CHEMBL3707357	Small molecule	Phase III	Moderate	80	—	ChEMBL	ChEMBL Open Targets
CHEMBL3833370	Small molecule	Phase III	Moderate	80	—	ChEMBL	ChEMBL Open Targets
CHEMBL3989689	Small molecule	Phase III	Moderate	80	—	ChEMBL	ChEMBL Open Targets
CHEMBL3989727	Small molecule	Phase III	Moderate	80	—	ChEMBL	ChEMBL Open Targets
CHEMBL4297684	Small molecule	Phase III	Moderate	80	—	ChEMBL	ChEMBL Open Targets
CHEMBL4297750	Small molecule	Phase III	Moderate	80	—	ChEMBL	ChEMBL Open Targets
CHEMBL495	Small molecule	Phase III	Moderate	80	—	ChEMBL	ChEMBL Open Targets
DEXMEDETOMIDINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
FENTANYL	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
FUROSEMIDE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
HYDROCORTISONE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ISAVUCONAZOLE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
KETAMINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
KETOROLAC	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
METHYLPREDNISOLONE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
METHYLPREDNISOLONE ACETATE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
MIDAZOLAM	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
OXYGEN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
PREDNISONE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
PROPOFOL	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
REMDESIVIR	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TOZORAKIMAB	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
DARAPLADIB Repurposing	Small molecule	Phase III	Moderate	70	—	ChEMBL	ChEMBL Open Targets
FENRETINIDE Repurposing	Small molecule	Phase III	Moderate	70	—	ChEMBL	ChEMBL Open Targets
HUMAN IMMUNOGLOBULIN G	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
APREMILAST	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CENICRIVIROC	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CHEMBL1009	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL1077	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL1200574	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL1200661	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL1200748	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL1201451	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL1201507	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL1201828	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL1393	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL140	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL1434	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL1456	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL165	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL1737	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL173929	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL1908360	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL1946170	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL2095222	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL2108678	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL2109321	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL2109570	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL223360	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL27	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL3545316	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL3545401	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL3545427	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL3670800	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL3989740	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL403989	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL4297313	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL4297529	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL4297587	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL4297889	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL4298012	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL4298063	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL4303669	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL4594457	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL4650436	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL477772	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL50	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL542541	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL6067961	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL989	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CYCLOSPORINE	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CYPROHEPTADINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DORNASE ALFA	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
FAMOTIDINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
FILGRASTIM	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
HEPARIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
IC14	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ICATIBANT	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ILOPROST	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
IMATINIB MESYLATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
IPRATROPIUM BROMIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
MAVRILIMUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
NARSOPLIMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
OBEFAZIMOD	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PLERIXAFOR	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
REMIMAZOLAM	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
REVEFENACIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SIVELESTAT SODIUM	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TELMISARTAN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TENECTEPLASE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ALPRENOLOL Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
AMIFLOXACIN Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
BROLAMFETAMINE Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
CARZENIDE Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
DIFLOXACIN Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
DIMECAMINE Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
ELLAGIC ACID Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
ENISOPROST Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
FENCAMFAMIN Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
FLEROXACIN Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
IDOXIFENE Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
LYSERGIDE Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
MERAFLOXACIN Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
TENAMFETAMINE Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
ZIDAPAMIDE Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
CHEMBL101253	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL1201575	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL1201576	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL1201834	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL1308	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL142464	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL2108061	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL2141712	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL253969	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL33864	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL367149	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL4298211	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL4584965	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
UPROLESELAN	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
XANTHOHUMOL	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
CHEMBL1675	Small molecule	Preclinical	Emerging	15	—	ChEMBL	ChEMBL Open Targets
LIDOCAINE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
NICARDIPINE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
REMIFENTANIL	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
SODIUM NITROPRUSSIDE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets

Drug	Type	Phase	Evidence	Score	Trials & literature	Sources	Links
CHEMBL5314346	Small molecule	Approved	Strong	100	No indexed hits View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL Open Targets
DEXAMETHASONE	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
PREDNISOLONE	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
TRIAMCINOLONE	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
TRIAMCINOLONE ACETONIDE	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
ACETAMINOPHEN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ALMITRINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
AVIPTADIL	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CELECOXIB	Small molecule	Phase III	Moderate	80	—	Open Targets, ChEMBL	ChEMBL Open Targets
CHEMBL1201421	Small molecule	Phase III	Moderate	80	—	ChEMBL	ChEMBL Open Targets
CHEMBL1201583	Small molecule	Phase III	Moderate	80	—	ChEMBL	ChEMBL Open Targets
CHEMBL1201825	Small molecule	Phase III	Moderate	80	—	ChEMBL	ChEMBL Open Targets
CHEMBL1293	Small molecule	Phase III	Moderate	80	—	ChEMBL	ChEMBL Open Targets
CHEMBL1742982	Small molecule	Phase III	Moderate	80	—	ChEMBL	ChEMBL Open Targets
CHEMBL196	Small molecule	Phase III	Moderate	80	—	ChEMBL	ChEMBL Open Targets
CHEMBL2106613	Small molecule	Phase III	Moderate	80	—	ChEMBL	ChEMBL Open Targets
CHEMBL2108313	Small molecule	Phase III	Moderate	80	—	ChEMBL	ChEMBL Open Targets
CHEMBL2110581	Small molecule	Phase III	Moderate	80	—	ChEMBL	ChEMBL Open Targets
CHEMBL25	Small molecule	Phase III	Moderate	80	—	ChEMBL	ChEMBL Open Targets
CHEMBL3301576	Small molecule	Phase III	Moderate	80	—	ChEMBL	ChEMBL Open Targets
CHEMBL3707357	Small molecule	Phase III	Moderate	80	—	ChEMBL	ChEMBL Open Targets
CHEMBL3833370	Small molecule	Phase III	Moderate	80	—	ChEMBL	ChEMBL Open Targets
CHEMBL3989689	Small molecule	Phase III	Moderate	80	—	ChEMBL	ChEMBL Open Targets
CHEMBL3989727	Small molecule	Phase III	Moderate	80	—	ChEMBL	ChEMBL Open Targets
CHEMBL4297684	Small molecule	Phase III	Moderate	80	—	ChEMBL	ChEMBL Open Targets
CHEMBL4297750	Small molecule	Phase III	Moderate	80	—	ChEMBL	ChEMBL Open Targets
CHEMBL495	Small molecule	Phase III	Moderate	80	—	ChEMBL	ChEMBL Open Targets
DEXMEDETOMIDINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
FENTANYL	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
FUROSEMIDE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
HYDROCORTISONE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ISAVUCONAZOLE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
KETAMINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
KETOROLAC	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
METHYLPREDNISOLONE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
METHYLPREDNISOLONE ACETATE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
MIDAZOLAM	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
OXYGEN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
PREDNISONE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
PROPOFOL	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
REMDESIVIR	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TOZORAKIMAB	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
HUMAN IMMUNOGLOBULIN G	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
APREMILAST	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CENICRIVIROC	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CHEMBL1009	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL1077	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL1200574	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL1200661	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL1200748	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL1201451	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL1201507	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL1201828	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL1393	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL140	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL1434	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL1456	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL165	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL1737	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL173929	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL1908360	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL1946170	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL2095222	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL2108678	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL2109321	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL2109570	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL223360	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL267936	Small molecule	Phase II	Emerging	60	No indexed hits View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL Open Targets
CHEMBL269732	Small molecule	Phase II	Emerging	60	No indexed hits View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL Open Targets
CHEMBL27	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL3545316	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL3545401	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL3545427	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL3670800	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL3989740	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL403989	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL413	Small molecule	Phase II	Emerging	60	No indexed hits View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL Open Targets
CHEMBL4297313	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL4297529	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL4297587	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL4297889	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL4298012	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL4298063	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL4303669	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL4594457	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL4650436	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL477772	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL50	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL542541	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL6067961	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL989	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CYCLOSPORINE	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CYPROHEPTADINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DORNASE ALFA	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
FAMOTIDINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
FILGRASTIM	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
HEPARIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
IC14	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ICATIBANT	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ILOPROST	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
IMATINIB MESYLATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
IPRATROPIUM BROMIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
MAVRILIMUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
NARSOPLIMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
OBEFAZIMOD	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PLERIXAFOR	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
REMIMAZOLAM	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
REVEFENACIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SIVELESTAT SODIUM	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TELMISARTAN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TENECTEPLASE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CHEMBL101253	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL1201575	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL1201576	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL1201834	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL1308	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL142464	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL2108061	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL2141712	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL253969	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL33864	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL367149	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL4298211	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL4584965	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
UPROLESELAN	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
XANTHOHUMOL	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
CHEMBL1675	Small molecule	Preclinical	Emerging	15	—	ChEMBL	ChEMBL Open Targets
LIDOCAINE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
NICARDIPINE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
REMIFENTANIL	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
SODIUM NITROPRUSSIDE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets

Drug	Type	Phase	Evidence	Score	Trials & literature	Sources	Links
ACEBUTOLOL Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	—
ACEBUTOLOL HYDROCHLORIDE Repurposing via ADRB1	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
ACETAZOLAMIDE Repurposing via ABL1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ACYCLOVIR Repurposing via ABL1	Small molecule	Approved	Strong	95	—	DGIdb	—
ADENOSINE TRIPHOSPHATE Repurposing via ABL1	Small molecule	Approved	Strong	95	—	DGIdb	—
ALBUTEROL SULFATE Repurposing via ADRB2	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
ALFUZOSIN Repurposing via ADRA1B	Small molecule	Approved	Strong	95	—	DGIdb	—
ALFUZOSIN HYDROCHLORIDE Repurposing via ADRA1B	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
AMIODARONE HYDROCHLORIDE Repurposing via ADRA1A	Small molecule	Approved	Strong	95	—	DGIdb	—
AMITRIPTYLINE HYDROCHLORIDE Repurposing via ADRA1A	Small molecule	Approved	Strong	95	—	DGIdb	—
AMPHETAMINE Repurposing via ABL1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
APOMORPHINE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	—
APRACLONIDINE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	—
APRACLONIDINE HYDROCHLORIDE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
ARBUTAMINE Repurposing via ADRB1	Small molecule	Approved	Strong	95	—	DGIdb	—
ARFORMOTEROL Repurposing via ADRB2	Small molecule	Approved	Strong	95	—	DGIdb	—
ARFORMOTEROL TARTRATE Repurposing via ADRB2	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
ASCIMINIB Repurposing via ABL1	Small molecule	Approved	Strong	95	—	DGIdb	—
ASCIMINIB HYDROCHLORIDE Repurposing via ABL1	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
ASENAPINE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	—
ATENOLOL Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	—
ATIPAMEZOLE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	—
ATROPINE Repurposing via ADRA2A	Small molecule	Approved	Strong	95	—	DGIdb	—
AXITINIB Repurposing via ABL1	Small molecule	Approved	Strong	95	—	DGIdb	—
AZACITIDINE Repurposing via ABL1	Small molecule	Approved	Strong	95	—	DGIdb	—
BENZPHETAMINE Repurposing via ADRA1A	Small molecule	Approved	Strong	95	—	DGIdb	—
BETAXOLOL Repurposing via ADRA2C	Small molecule	Approved	Strong	95	2 Trial pubs 2 RCT View evidence Published literature Clinical trial publication [Serum lipid profile in non-exudative AMD patients treated with locally administrated beta-blockers] (Klinika oczna, 2004) Clinical trial publication Randomized clinical trial of topical betaxolol for persistent macular edema after vitrectomy and epiretinal membrane removal (American journal of ophthalmology, 2003) CT.gov search · Cochrane · PubMed	DGIdb	—
BETAXOLOL HYDROCHLORIDE Repurposing via ADRB1	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
BETHANIDINE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	—
BICALUTAMIDE Repurposing via ABL1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
BISOPROLOL Repurposing via ADRA2C	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
BISOPROLOL FUMARATE Repurposing via ADRB1	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
BITOLTEROL MESYLATE Repurposing via ADRB2	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
BLINATUMOMAB Repurposing via ABL1	Small molecule	Approved	Strong	95	—	DGIdb	—
BOSUTINIB Repurposing via ABL1	Small molecule	Approved	Strong	95	—	DGIdb	—
BOSUTINIB MONOHYDRATE Repurposing via ABL1	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
BRETYLIUM Repurposing via ADRB1	Small molecule	Approved	Strong	95	—	DGIdb	—
BRIMONIDINE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	4 trials 6 Trial pubs 5 RCT View evidence Registry trials NCT00864838 — Oral Acetazolamide, Brimonidine Tartarate, and Anterior Chamber Paracentesis for Ocular Hypertension Control After Intravitreal Bevacizumab (COMPLETED) PHASE2 NCT00804921 — Effectiveness of Oral Acetazolamide, Brimonidine Tartarate, and Anterior Chamber Paracentesis in Intraocular Pressure (IOP) After Bevacizumab (COMPLETED) PHASE2 NCT02087085 — A Safety and Efficacy Study of Brimonidine Intravitreal Implant in Geographic Atrophy Secondary to Age-related Macular Degeneration (TERMINATED) PHASE2 NCT00658619 — Safety and Efficacy of Brimonidine Intravitreal Implant in Patients With Geographic Atrophy Due to Age-related Macular Degeneration (AMD) (COMPLETED) PHASE2 Published literature Clinical trial publication Randomized Phase IIb Study of Brimonidine Drug Delivery System Generation 2 for Geographic Atrophy in Age-Related Macular Degeneration (Ophthalmology. Retina, 2023) Clinical trial publication PHASE 2 STUDY OF THE SAFETY AND EFFICACY OF BRIMONIDINE DRUG DELIVERY SYSTEM (BRIMO DDS) GENERATION 1 IN PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION (Retina (Philadelphia, Pa.), 2021) Clinical trial publication Hypotensive efficacy of topical brimonidine for intraocular pressure spikes following intravitreal injections of antivascular endothelial growth factor agents: a randomised crossover trial (The British journal of ophthalmology, 2019) Clinical trial publication Role of brimonidine in the treatment of clinically significant macular edema with ischemic changes in diabetic maculopathy (International ophthalmology, 2014) Clinical trial publication Comparison of dorzolamide/timolol versus brimonidine/timolol fixed combination therapy in the management of steroid-induced ocular hypertension (Journal of glaucoma, 2015) CT.gov search · Cochrane · PubMed	DGIdb	—
BRIMONIDINE TARTRATE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
BROMOCRIPTINE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	—
BUSULFAN Repurposing via ABL1	Small molecule	Approved	Strong	95	—	DGIdb	—
CABERGOLINE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	—
CABOZANTINIB S-MALATE Repurposing via ABL1	Small molecule	Approved	Strong	95	—	DGIdb	—
CARBACHOL Repurposing via ABL1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
CARTEOLOL Repurposing via ADRB2	Small molecule	Approved	Strong	95	—	DGIdb	—
CARTEOLOL HYDROCHLORIDE Repurposing via ADRB2	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
CARVEDILOL Repurposing via ADRA2C	Small molecule	Approved	Strong	95	1 pubs View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
CARVEDILOL PHOSPHATE Repurposing via ADRB2	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
CELECOXIB Repurposing via ABL1	Small molecule	Approved	Strong	95	—	DGIdb	—
CELIPROLOL Repurposing via ADRA2C	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
CHLORPROMAZINE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	—
CIPROFLOXACIN Repurposing via ABL1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
CLOMIPRAMINE Repurposing via ADRA1A	Small molecule	Approved	Strong	95	—	DGIdb	—
CLOMIPRAMINE Repurposing via ABL1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
CLONIDINE HYDROCHLORIDE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
CLOTRIMAZOLE Repurposing via ADRB2	Small molecule	Approved	Strong	95	—	DGIdb	—
CLOZAPINE Repurposing via ADRA1B	Small molecule	Approved	Strong	95	—	DGIdb	—
CRIZOTINIB Repurposing via ABL1	Small molecule	Approved	Strong	95	—	DGIdb	—
CYCLOBENZAPRINE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
CYPROHEPTADINE HYDROCHLORIDE Repurposing via ADRA1B	Small molecule	Approved	Strong	95	—	DGIdb	—
DAPIPRAZOLE Repurposing via ADRA1B	Small molecule	Approved	Strong	95	—	DGIdb	—
DAPIPRAZOLE HYDROCHLORIDE Repurposing via ADRA1A	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
DASATINIB ANHYDROUS Repurposing via ABL1	Small molecule	Approved	Strong	95	—	DGIdb	—
DEBRISOQUIN Repurposing via ADRA2C	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
DESIPRAMINE Repurposing via ADRB2	Small molecule	Approved	Strong	95	—	DGIdb	—
DEXMEDETOMIDINE HYDROCHLORIDE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
DEXTROAMPHETAMINE SULFATE Repurposing via ADRA1A	Small molecule	Approved	Strong	95	—	DGIdb	—
DIAZEPAM Repurposing via ABL1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
DICHLORPHENAMIDE Repurposing via ABL1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
DIENESTROL Repurposing via ADRB2	Small molecule	Approved	Strong	95	—	DGIdb	—
DIETHYLSTILBESTROL Repurposing via ABL1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
DILEVALOL HYDROCHLORIDE Repurposing via ADRB2	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
DIPIVEFRIN Repurposing via ADRA2A	Small molecule	Approved	Strong	95	—	DGIdb	—
DIPIVEFRIN HYDROCHLORIDE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
DISULFIRAM Repurposing via ADRB2	Small molecule	Approved	Strong	95	—	DGIdb	—
DOBUTAMINE Repurposing via ADRB1	Small molecule	Approved	Strong	95	—	DGIdb	—
DOBUTAMINE HYDROCHLORIDE Repurposing via ADRB2	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
DOPAMINE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	—
DOPAMINE HYDROCHLORIDE Repurposing via ADRB1	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
DOXAZOSIN MESYLATE Repurposing via ADRA1B	Small molecule	Approved	Strong	95	—	DGIdb	—
DOXAZOSIN MESYLATE Repurposing via ADRA1A	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
DRONEDARONE Repurposing via ADRA1A	Small molecule	Approved	Strong	95	—	DGIdb	—
DROXIDOPA Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	—
ENALAPRIL MALEATE Repurposing via ADRB2	Small molecule	Approved	Strong	95	—	DGIdb	—
ENTRECTINIB Repurposing via ABL1	Small molecule	Approved	Strong	95	—	DGIdb	—
EPHEDRINE Repurposing via ADRB2	Small molecule	Approved	Strong	95	—	DGIdb	—
EPHEDRINE HYDROCHLORIDE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
EPHEDRINE SULFATE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
EPINEPHRINE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	—
EPINEPHRINE BITARTRATE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
EPIRUBICIN Repurposing via ABL1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ERGOLOID MESYLATES Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
ERGOLOID MESYLATES, USP Repurposing via ADRA1A	Small molecule	Approved	Strong	95	—	DGIdb	—
ERGOTAMINE Repurposing via ADRA1D	Small molecule	Approved	Strong	95	—	DGIdb	—
ERGOTAMINE TARTRATE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	ChEMBL Open Targets
ERLOTINIB Repurposing via ABL1	Small molecule	Approved	Strong	95	—	DGIdb	—
ESMOLOL Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	—
ESMOLOL HYDROCHLORIDE Repurposing via ADRB2	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
ETHOXZOLAMIDE Repurposing via ABL1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ETOMIDATE Repurposing via ADRA2B	Small molecule	Approved	Strong	95	—	DGIdb	—
FENOLDOPAM Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	—
FENOTEROL Repurposing via ADRB2	Small molecule	Approved	Strong	95	—	DGIdb	—
FLECAINIDE ACETATE Repurposing via ADRB1	Small molecule	Approved	Strong	95	—	DGIdb	—
FLUMAZENIL Repurposing via ABL1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
FORMOTEROL FUMARATE Repurposing via ADRB2	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
FORMOTEROL FUMARATE Repurposing via ADRB1	Small molecule	Approved	Strong	95	—	DGIdb	—
FOSLEVODOPA Repurposing via ADRB1	Small molecule	Approved	Strong	95	—	DGIdb	—
GENISTEIN Repurposing via ABL1	Small molecule	Approved	Strong	95	—	DGIdb	—
GLYCOPYRRONIUM BROMIDE Repurposing via ADRB2	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
GUANABENZ Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	—
GUANABENZ ACETATE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
GUANFACINE HYDROCHLORIDE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
GUANFACINE HYDROCHLORIDE Repurposing via ADRA2A	Small molecule	Approved	Strong	95	—	DGIdb	—
HYDROXYAMPHETAMINE HYDROBROMIDE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
HYDROXYUREA Repurposing via ABL1	Small molecule	Approved	Strong	95	—	DGIdb	—
ILOPERIDONE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
IMATINIB Repurposing via ABL1	Small molecule	Approved	Strong	95	—	DGIdb	—
IMATINIB MESYLATE Repurposing via ABL1	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
IMIPRAMINE Repurposing via ABL1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
INDACATEROL Repurposing via ADRB2	Small molecule	Approved	Strong	95	—	DGIdb	—
INDACATEROL MALEATE Repurposing via ADRB2	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
INDAPAMIDE Repurposing via ABL1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
INDOMETHACIN Repurposing via ABL1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
INOTUZUMAB OZOGAMICIN Repurposing via ABL1	Small molecule	Approved	Strong	95	—	DGIdb	—
ISOETHARINE Repurposing via ADRB2	Small molecule	Approved	Strong	95	—	DGIdb	—
ISOETHARINE HYDROCHLORIDE Repurposing via ADRB2	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
ISOETHARINE MESYLATE Repurposing via ADRB2	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
ISOPROTERENOL Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	—
ISOPROTERENOL HYDROCHLORIDE Repurposing via ADRB2	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
ISOPROTERENOL SULFATE Repurposing via ADRB2	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
ISOSORBIDE DINITRATE Repurposing via ABL1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
LABETALOL Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	—
LABETALOL HYDROCHLORIDE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
LANDIOLOL Repurposing via ADRB1	Small molecule	Approved	Strong	95	—	DGIdb	—
LANDIOLOL HYDROCHLORIDE Repurposing via ADRB1	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
LEVALBUTEROL Repurposing via ADRB2	Small molecule	Approved	Strong	95	—	DGIdb	—
LEVALBUTEROL HYDROCHLORIDE Repurposing via ADRB2	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
LEVALBUTEROL TARTRATE Repurposing via ADRB2	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
LEVOBETAXOLOL HYDROCHLORIDE Repurposing via ADRB1	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
LEVOBUNOLOL Repurposing via ADRB2	Small molecule	Approved	Strong	95	—	DGIdb	—
LEVOBUNOLOL HYDROCHLORIDE Repurposing via ADRB2	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
LEVONORDEFRIN Repurposing via ADRA2C	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
LISDEXAMFETAMINE DIMESYLATE Repurposing via ADRA1B	Small molecule	Approved	Strong	95	—	DGIdb	—
LOFEXIDINE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	—
LOFEXIDINE HYDROCHLORIDE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	ChEMBL Open Targets
LURASIDONE HYDROCHLORIDE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	—
MAFENIDE Repurposing via ABL1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
MECAMYLAMINE Repurposing via ABL1	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL Open Targets
MELPHALAN Repurposing via ABL1	Small molecule	Approved	Strong	95	—	DGIdb	—
MEPERIDINE HYDROCHLORIDE Repurposing via ADRA2A	Small molecule	Approved	Strong	95	—	DGIdb	—
MEPHENTERMINE Repurposing via ADRA1A	Small molecule	Approved	Strong	95	—	DGIdb	—
MEPHENTERMINE SULFATE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
MEPOLIZUMAB Repurposing via ADRB2	Small molecule	Approved	Strong	95	—	DGIdb	—
METAPROTERENOL Repurposing via ADRB2	Small molecule	Approved	Strong	95	—	DGIdb	—
METAPROTERENOL SULFATE Repurposing via ADRB2	Small molecule	Approved	Strong	95	—	DGIdb	—
METARAMINOL Repurposing via ADRA1A	Small molecule	Approved	Strong	95	—	DGIdb	—
METARAMINOL BITARTRATE Repurposing via ADRA1B	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
METHACHOLINE Repurposing via ADRB2	Small molecule	Approved	Strong	95	—	DGIdb	—
METHAMPHETAMINE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	—
METHAZOLAMIDE Repurposing via ABL1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
METHOTRIMEPRAZINE Repurposing via ADRA1B	Small molecule	Approved	Strong	95	—	DGIdb	—
METHOXAMINE Repurposing via ADRA1B	Small molecule	Approved	Strong	95	—	DGIdb	—
METHOXAMINE HYDROCHLORIDE Repurposing via ADRA1B	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
METHOXSALEN Repurposing via ABL1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
METHYLDOPA ANHYDROUS Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	—
METHYLDOPATE HYDROCHLORIDE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
METIPRANOLOL Repurposing via ADRB2	Small molecule	Approved	Strong	95	—	DGIdb	—
METIPRANOLOL HYDROCHLORIDE Repurposing via ADRB2	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
METOPROLOL Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	—
METOPROLOL Repurposing via ABL1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
METOPROLOL FUMARATE Repurposing via ADRB1	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
METOPROLOL SUCCINATE Repurposing via ADRA1D	Small molecule	Approved	Strong	95	—	DGIdb	—
METOPROLOL SUCCINATE Repurposing via ADRB1	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
METOPROLOL TARTRATE Repurposing via ADRB1	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
MIANSERIN Repurposing via ABL1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
MIDODRINE Repurposing via ADRA1B	Small molecule	Approved	Strong	95	—	DGIdb	—
MIDODRINE HYDROCHLORIDE Repurposing via ADRA1B	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
MILNACIPRAN Repurposing via ADRA2A	Small molecule	Approved	Strong	95	—	DGIdb	—
MIRABEGRON Repurposing via ADRB2	Small molecule	Approved	Strong	95	—	DGIdb	—
MIRTAZAPINE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	—
MODAFINIL Repurposing via ADRA1D	Small molecule	Approved	Strong	95	—	DGIdb	—
MOXISYLYTE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	—
MOXONIDINE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
NADOLOL Repurposing via ADRA2C	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
NADOLOL Repurposing via ADRB1	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
NAFTOPIDIL Repurposing via ADRA1D	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
NALIDIXIC ACID Repurposing via ABL1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
NAPHAZOLINE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	—
NAPHAZOLINE HYDROCHLORIDE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
NEBIVOLOL HYDROCHLORIDE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	—
NEBIVOLOL HYDROCHLORIDE Repurposing via ADRB2	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
NEFAZODONE Repurposing via ADRA1B	Small molecule	Approved	Strong	95	—	DGIdb	—
NICOTINE Repurposing via ABL1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
NIFEDIPINE Repurposing via ADRA1A	Small molecule	Approved	Strong	95	—	DGIdb	—
NILOTINIB Repurposing via ABL1	Small molecule	Approved	Strong	95	—	DGIdb	—
NILOTINIB HYDROCHLORIDE MONOHYDRATE Repurposing via ABL1	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
NOREPINEPHRINE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	3 pubs View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
NOREPINEPHRINE BITARTRATE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
NORFLOXACIN Repurposing via ABL1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
NORTRIPTYLINE Repurposing via ADRA1A	Small molecule	Approved	Strong	95	—	DGIdb	—
OFLOXACIN Repurposing via ABL1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
OLANZAPINE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	1 pubs View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
OLODATEROL Repurposing via ADRB2	Small molecule	Approved	Strong	95	—	DGIdb	—
OLODATEROL HYDROCHLORIDE Repurposing via ADRB2	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
OMACETAXINE Repurposing via ABL1	Small molecule	Approved	Strong	95	—	DGIdb	—
OMACETAXINE MEPESUCCINATE Repurposing via ABL1	Small molecule	Approved	Strong	95	—	DGIdb	—
OXALIPLATIN Repurposing via ABL1	Small molecule	Approved	Strong	95	—	DGIdb	—
OXPRENOLOL Repurposing via ADRB2	Small molecule	Approved	Strong	95	—	DGIdb	—
OXPRENOLOL HYDROCHLORIDE Repurposing via ADRB2	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
OXYMETAZOLINE HYDROCHLORIDE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	—
OXYMETAZOLINE HYDROCHLORIDE Repurposing via ADRA2B	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
PAPAVERINE Repurposing via ADRA1D	Small molecule	Approved	Strong	95	—	DGIdb	—
PAZOPANIB Repurposing via ABL1	Small molecule	Approved	Strong	95	—	DGIdb	—
PENBUTOLOL Repurposing via ADRB2	Small molecule	Approved	Strong	95	—	DGIdb	—
PENBUTOLOL SULFATE Repurposing via ADRB2	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
PERGOLIDE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	—
PHENDIMETRAZINE Repurposing via ADRA1B	Small molecule	Approved	Strong	95	—	DGIdb	—
PHENOXYBENZAMINE Repurposing via ADRA2B	Small molecule	Approved	Strong	95	—	DGIdb	—
PHENOXYBENZAMINE HYDROCHLORIDE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
PHENTOLAMINE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	—
PHENTOLAMINE MESYLATE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
PHENYLEPHRINE Repurposing via ADRA1B	Small molecule	Approved	Strong	95	—	DGIdb	—
PHENYLEPHRINE BITARTRATE Repurposing via ADRA1B	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
PHENYLEPHRINE HYDROCHLORIDE Repurposing via ADRB2	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
PHENYLPROPANOLAMINE Repurposing via ADRA1A	Small molecule	Approved	Strong	95	—	DGIdb	—
PHENYLPROPANOLAMINE HYDROCHLORIDE Repurposing via ADRA1A	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
PHENYLPROPANOLAMINE POLISTIREX Repurposing via ADRA1A	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
PHENYTOIN Repurposing via ABL1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
PINDOLOL Repurposing via ADRA2C	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
PIRBUTEROL Repurposing via ADRB2	Small molecule	Approved	Strong	95	—	DGIdb	—
PIRBUTEROL ACETATE Repurposing via ADRB2	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
PONATINIB Repurposing via ABL1	Small molecule	Approved	Strong	95	—	DGIdb	—
PONATINIB HYDROCHLORIDE Repurposing via ABL1	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
PRACTOLOL Repurposing via ADRB1	Small molecule	Approved	Strong	95	—	DGIdb	—
PRAZOSIN Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	—
PRAZOSIN Repurposing via ABL1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
PRAZOSIN HYDROCHLORIDE Repurposing via ADRA1B	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
PRILOCAINE HYDROCHLORIDE Repurposing via ADRB2	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
PROGESTERONE Repurposing via ABL1	Small molecule	Approved	Strong	95	—	DGIdb	—
PROMAZINE Repurposing via ADRA1B	Small molecule	Approved	Strong	95	—	DGIdb	—
PRONETALOL Repurposing via ADRB2	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
PROPAFENONE Repurposing via ADRB2	Small molecule	Approved	Strong	95	—	DGIdb	—
PROPAFENONE HYDROCHLORIDE Repurposing via ADRB2	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
PROPIOMAZINE Repurposing via ADRA1B	Small molecule	Approved	Strong	95	—	DGIdb	—
PROPRANOLOL HYDROCHLORIDE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	1 trials View evidence Registry trials NCT03609307 — Comparison of Treatment Response to Intravitreal Injection of Combined Propranolol and Bevacizumab Versus Bevacizumab Monotherapy in Patients With Wet Age Related Macular Degeneration :A Clinical Trial (UNKNOWN) PHASE2, PHASE3 CT.gov search · Cochrane · PubMed	DGIdb	—
PROPRANOLOL HYDROCHLORIDE Repurposing via ADRB2	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
PROPYLHEXEDRINE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	—
PROTOKYLOL HYDROCHLORIDE Repurposing via ADRB2	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
PSEUDOEPHEDRINE POLISTIREX Repurposing via ADRB2	Small molecule	Approved	Strong	95	—	DGIdb	—
QUETIAPINE FUMARATE Repurposing via ADRA1B	Small molecule	Approved	Strong	95	—	DGIdb	—
RACEPINEPHRINE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	—
RAMIPRIL Repurposing via ADRB2	Small molecule	Approved	Strong	95	—	DGIdb	—
RAUWOLFIA SERPENTINA Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
RAUWOLFIA SERPENTINA (USP) Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	—
REGORAFENIB Repurposing via ABL1	Small molecule	Approved	Strong	95	—	DGIdb	—
REMIFENTANIL HYDROCHLORIDE Repurposing via ADRA2A	Small molecule	Approved	Strong	95	—	DGIdb	—
RILMENIDINE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	—
RISPERIDONE Repurposing via ADRB2	Small molecule	Approved	Strong	95	—	DGIdb	—
RITODRINE Repurposing via ADRB2	Small molecule	Approved	Strong	95	—	DGIdb	—
RITODRINE HYDROCHLORIDE Repurposing via ADRB2	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
SALMETEROL Repurposing via ADRB2	Small molecule	Approved	Strong	95	—	DGIdb	—
SALMETEROL XINAFOATE Repurposing via ADRB2	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
SERTINDOLE Repurposing via ADRA1B	Small molecule	Approved	Strong	95	—	DGIdb	—
SILODOSIN Repurposing via ADRA1B	Small molecule	Approved	Strong	95	—	DGIdb	—
SIROLIMUS Repurposing via ABL1	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL Open Targets
SODIUM CHLORIDE Repurposing via ADRB2	Small molecule	Approved	Strong	95	—	DGIdb	—
SORAFENIB Repurposing via ABL1	Small molecule	Approved	Strong	95	—	DGIdb	—
SOTALOL Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	—
SOTALOL HYDROCHLORIDE Repurposing via ADRB2	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
SUFENTANIL Repurposing via ADRB1	Small molecule	Approved	Strong	95	—	DGIdb	—
SULBACTAM Repurposing via ABL1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
TACROLIMUS ANHYDROUS Repurposing via ABL1	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL Open Targets
TAMSULOSIN HYDROCHLORIDE Repurposing via ADRA1B	Small molecule	Approved	Strong	95	—	DGIdb	—
TAMSULOSIN HYDROCHLORIDE Repurposing via ADRA1A	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
TAZOBACTAM Repurposing via ABL1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
TERAZOSIN Repurposing via ADRA1B	Small molecule	Approved	Strong	95	—	DGIdb	—
TERAZOSIN HYDROCHLORIDE Repurposing via ADRA1B	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
TERBUTALINE Repurposing via ADRB2	Small molecule	Approved	Strong	95	—	DGIdb	—
TERBUTALINE SULFATE Repurposing via ADRB2	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
TETRAHYDROZOLINE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	—
TETRAHYDROZOLINE HYDROCHLORIDE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
THIORIDAZINE Repurposing via ADRA1A	Small molecule	Approved	Strong	95	—	DGIdb	—
TIMOLOL Repurposing via ADRB2	Small molecule	Approved	Strong	95	—	DGIdb	—
TIMOLOL MALEATE Repurposing via ADRB2	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
TIOTROPIUM Repurposing via ADRB2	Small molecule	Approved	Strong	95	—	DGIdb	—
TIZANIDINE HYDROCHLORIDE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	—
TIZANIDINE HYDROCHLORIDE Repurposing via ADRA2B	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
TOLAZOLINE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	—
TOLAZOLINE HYDROCHLORIDE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
TRAMETINIB DIMETHYL SULFOXIDE Repurposing via ABL1	Small molecule	Approved	Strong	95	—	DGIdb	—
TRAZODONE Repurposing via ADRA1B	Small molecule	Approved	Strong	95	—	DGIdb	—
TRIFLUOPERAZINE Repurposing via ADRA1A	Small molecule	Approved	Strong	95	—	DGIdb	—
TRIMIPRAMINE MALEATE Repurposing via ADRA1B	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
TROGLITAZONE Repurposing via ABL1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
UMBRALISIB TOSYLATE Repurposing via ABL1	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
VANDETANIB Repurposing via ABL1	Small molecule	Approved	Strong	95	—	DGIdb	—
VENETOCLAX Repurposing via ABL1	Small molecule	Approved	Strong	95	—	DGIdb	—
VILANTEROL Repurposing via ADRB2	Small molecule	Approved	Strong	95	—	DGIdb	—
VILANTEROL TRIFENATATE Repurposing via ADRB2	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
VINCRISTINE Repurposing via ABL1	Small molecule	Approved	Strong	95	—	DGIdb	—
XYLAZINE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
XYLOMETAZOLINE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	—
XYLOMETAZOLINE HYDROCHLORIDE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
YOHIMBINE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
ZIPRASIDONE Repurposing via ADRA1A	Small molecule	Approved	Strong	95	—	DGIdb	—
DARAPLADIB Repurposing via ABL1	Small molecule	Phase III	Moderate	70	—	ChEMBL	ChEMBL Open Targets
FENRETINIDE Repurposing via ABL1	Small molecule	Phase III	Moderate	70	—	ChEMBL	ChEMBL Open Targets
ALPRENOLOL Repurposing via ABL1	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
AMIFLOXACIN Repurposing via ABL1	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
BROLAMFETAMINE Repurposing via ABL1	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
CARZENIDE Repurposing via ABL1	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
DIFLOXACIN Repurposing via ABL1	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
DIMECAMINE Repurposing via ABL1	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
ELLAGIC ACID Repurposing via ABL1	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
ENISOPROST Repurposing via ABL1	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
FENCAMFAMIN Repurposing via ABL1	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
FLEROXACIN Repurposing via ABL1	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
IDOXIFENE Repurposing via ABL1	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
LYSERGIDE Repurposing via ABL1	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
MERAFLOXACIN Repurposing via ABL1	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
TENAMFETAMINE Repurposing via ABL1	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
ZIDAPAMIDE Repurposing via ABL1	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets

Natural Products

127 natural products with the same evidence schema as repurposed drugs — registry trials, PubMed literature, and reference links (pipeline-ranked). Only agents with direct clinical evidence are shown by default.

Reference lookups: Examine.com

Show agents without direct trial evidence

Drug	Type	Phase	Evidence	Score	Trials & literature	Sources	Links
Lutein Natural product Meta-analysis The Effect of Dietary Supplementations on Delaying the Progression of A… Meta-analysis Efficacy of different nutrients in age-related macular degeneration: A… Meta-analysis Effects of lutein supplementation in age-related macular degeneration	Nutraceutical	Preclinical	Emerging	10	8 trials 12 Meta-analysis View evidence Registry trials NCT04741763 — "Night Vision and Carotenoids" (COMPLETED) NA NCT06237127 — Effects of Goji vs. Fiber on Macular Degeneration (RECRUITING) NA NCT06489873 — Lutein, Zeaxathin, and Fish Oil Supplementation (RECRUITING) NA NCT02113254 — Study of the Macular Pigment by the Consumption of Corn With Strong Content in Zeaxanthine (TERMINATED) NA NCT02264938 — Drusen Morphology Changes in Nonexudative Age-related Degeneration After Oral Antioxidants Supplementation (COMPLETED) NA NCT00443911 — Rheohemapheresis and Lutein Supplementation in the Non-Exsudative Form of Age-Related Macular Degeneration (UNKNOWN) NCT00879671 — Effects of Lutein Supplementation on Macular Pigment Optical Density and Visual Acuity in Patients With Age-related Macular Degeneration (COMPLETED) NA NCT05283941 — Pistachios and Neural Macular Pigment (UNKNOWN) NA Published literature Meta-analysis The Effect of Dietary Supplementations on Delaying the Progression of Age-Related Macular Degeneration: A Systematic Review and Meta-Analysis (Nutrients, 2022) Meta-analysis Efficacy of different nutrients in age-related macular degeneration: A systematic review and network meta-analysis (Seminars in ophthalmology, 2022) Meta-analysis Effects of lutein supplementation in age-related macular degeneration (PloS one, 2019) Meta-analysis Dietary guidance for lutein: consideration for intake recommendations is scientifically supported (European journal of nutrition, 2017) Meta-analysis Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration (The Cochrane database of systematic reviews, 2017) CT.gov search · Cochrane · PubMed	ClinicalTrials.gov	PubChem
Vitamin D3 Natural product Human Study Dietary intake of B vitamins may affect the occurrence of age-related l… Human Study Supplementation with vitamin C, E, beta-carontene and zinc demonstrates… Animal Study Antioxidant vitamin and mineral supplements for slowing the progression…	Nutraceutical	Phase III	Emerging	10	8 trials View evidence Registry trials NCT04239625 — Open-Label Extension: Tolerability and Effects of ALK-001 on Stargardt Disease (TEASE) (ACTIVE_NOT_RECRUITING) PHASE2 NCT04482465 — Omega 3 and Vitamin D Dosage in a Population With Moderate to High Risk of AMD (COMPLETED) NA NCT01782352 — Age-related Macular Degeneration (AMD) in the Vitamin D and Omega-3 Trial (VITAL) (UNKNOWN) NA NCT02402660 — Phase 2 Tolerability and Effects of ALK-001 on Stargardt Disease (ENROLLING_BY_INVITATION) PHASE2 NCT01524874 — Comparative Effectiveness of Vitamin D and Repletion Strategies (COMPLETED) NA NCT03845582 — Phase 2/3 Study of ALK-001 in Geographic Atrophy (COMPLETED) PHASE2, PHASE3 NCT02230228 — Phase 1 Safety Study of ALK-001 in Healthy Volunteers (COMPLETED) PHASE1 NCT04177069 — Evaluate the Improving Effects of Visucomplex Plus on Quality of Life in Patients With AMD (UNKNOWN) CT.gov search · Cochrane · PubMed	ClinicalTrials.gov	PubChem
Omega-3 Fatty Acids Natural product Cochrane review Can Omega-3 Fatty Acids Serve as a Preventive Strategy for Age-Related… Cochrane review The Effect of Dietary Supplementations on Delaying the Progression of A… Cochrane review What did we learn in 35 years of research on nutrition and supplements…	Nutraceutical	Phase III	Emerging	10	8 trials 10 Cochrane View evidence Registry trials NCT05763940 — Efficacy of OmegaBoost to Increase Omega-3 Levels in Healthy Individuals (UNKNOWN) NA NCT01258335 — Omega-3-fatty Acids on Age-related Macular (COMPLETED) NA NCT02264938 — Drusen Morphology Changes in Nonexudative Age-related Degeneration After Oral Antioxidants Supplementation (COMPLETED) NA NCT00345176 — Age-Related Eye Disease Study 2 (AREDS2) (COMPLETED) PHASE3 NCT03297515 — Therapeutic Potential of Omega-3 Fatty Acids Supplementation in Dry Macular Degeneration and Stargardt Disease (COMPLETED) NA NCT05465252 — Effect of Omega-3 Fatty Acid Supplementation on Dry-AMD Progression (RECRUITING) NA NCT01819415 — Omega-3 Supplementation and Vitreal VEGF Levels in Wet-AMD (COMPLETED) NA NCT01653184 — Effect of Omega-3-fatty Acids on Blood Levels Omega-3 Fatty Acids in Patients With Age-related Macular Degeneration (COMPLETED) NA Published literature Cochrane review Can Omega-3 Fatty Acids Serve as a Preventive Strategy for Age-Related Macular Degeneration? A Systematic Review and Meta-Analysis (The Journal of nutrition, 2026) Cochrane review The Effect of Dietary Supplementations on Delaying the Progression of Age-Related Macular Degeneration: A Systematic Review and Meta-Analysis (Nutrients, 2022) Cochrane review What did we learn in 35 years of research on nutrition and supplements for age-related macular degeneration: a systematic review (Acta ophthalmologica, 2022) Cochrane review What do Cochrane systematic reviews say about interventions for age-related macular degeneration? (Sao Paulo medical journal = Revista paulista de medicina, 2019) Cochrane review Omega 3 fatty acids for preventing or slowing the progression of age-related macular degeneration (The Cochrane database of systematic reviews, 2015) CT.gov search · Cochrane · PubMed	ClinicalTrials.gov	PubChem
Lutein Natural product Meta-analysis The Effect of Dietary Supplementations on Delaying the Progression of A… Meta-analysis Efficacy of different nutrients in age-related macular degeneration: A… Meta-analysis Effects of lutein supplementation in age-related macular degeneration	Nutraceutical	Preclinical	Emerging	10	8 trials 12 Meta-analysis View evidence Registry trials NCT04741763 — "Night Vision and Carotenoids" (COMPLETED) NA NCT06237127 — Effects of Goji vs. Fiber on Macular Degeneration (RECRUITING) NA NCT06489873 — Lutein, Zeaxathin, and Fish Oil Supplementation (RECRUITING) NA NCT02113254 — Study of the Macular Pigment by the Consumption of Corn With Strong Content in Zeaxanthine (TERMINATED) NA NCT02264938 — Drusen Morphology Changes in Nonexudative Age-related Degeneration After Oral Antioxidants Supplementation (COMPLETED) NA NCT00443911 — Rheohemapheresis and Lutein Supplementation in the Non-Exsudative Form of Age-Related Macular Degeneration (UNKNOWN) NCT00879671 — Effects of Lutein Supplementation on Macular Pigment Optical Density and Visual Acuity in Patients With Age-related Macular Degeneration (COMPLETED) NA NCT05283941 — Pistachios and Neural Macular Pigment (UNKNOWN) NA Published literature Meta-analysis The Effect of Dietary Supplementations on Delaying the Progression of Age-Related Macular Degeneration: A Systematic Review and Meta-Analysis (Nutrients, 2022) Meta-analysis Efficacy of different nutrients in age-related macular degeneration: A systematic review and network meta-analysis (Seminars in ophthalmology, 2022) Meta-analysis Effects of lutein supplementation in age-related macular degeneration (PloS one, 2019) Meta-analysis Dietary guidance for lutein: consideration for intake recommendations is scientifically supported (European journal of nutrition, 2017) Meta-analysis Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration (The Cochrane database of systematic reviews, 2017) CT.gov search · Cochrane · PubMed		PubChem
Zinc Natural product Randomized controlled trial No CFH or ARMS2 Interaction with Omega-3 Fatty Acids, Low versus High Z… Randomized controlled trial Effects of Macuprev(®) Supplementation in Age-Related Macular Degenerat… Human Study A combination of nutrients improves age-related macular degeneration.	Nutraceutical	Approved	Emerging	10	8 trials 46 Trial pubs 41 RCT View evidence Registry trials NCT00000145 — Age-Related Eye Disease Study (AREDS) (COMPLETED) PHASE3 NCT02264938 — Drusen Morphology Changes in Nonexudative Age-related Degeneration After Oral Antioxidants Supplementation (COMPLETED) NA NCT04482465 — Omega 3 and Vitamin D Dosage in a Population With Moderate to High Risk of AMD (COMPLETED) NA NCT01653184 — Effect of Omega-3-fatty Acids on Blood Levels Omega-3 Fatty Acids in Patients With Age-related Macular Degeneration (COMPLETED) NA NCT06391411 — Effect of Micronutrient Supplementation on the Intestinal Microbiota in Patients With Age-related Macular Degeneration - The Gut-Retina-axis Study (COMPLETED) NA NCT00478439 — Investigation of Macular Pigment Augmentation on Dark Adaptation (TERMINATED) PHASE4 NCT02625376 — Resveratrol for Exudative Age-Related Macular Degeneration (TERMINATED) NA NCT04177069 — Evaluate the Improving Effects of Visucomplex Plus on Quality of Life in Patients With AMD (UNKNOWN) Published literature Randomized controlled trial No CFH or ARMS2 Interaction with Omega-3 Fatty Acids, Low versus High Zinc, or β-Carotene versus Lutein and Zeaxanthin on Progression of Age-Related Macular Degeneration in the Age-Related Eye Disease Study 2: Age-Related Eye Disease Study 2 Report No. 18 (Ophthalmology, 2019) Randomized controlled trial Effects of Macuprev(®) Supplementation in Age-Related Macular Degeneration: A Double-Blind Randomized Morpho-Functional Study Along 6 Months of Follow-Up (Advances in therapy, 2019) CT.gov search · Cochrane · PubMed		PubChem
Omega-3 Fatty Acids Natural product Cochrane review Can Omega-3 Fatty Acids Serve as a Preventive Strategy for Age-Related… Cochrane review The Effect of Dietary Supplementations on Delaying the Progression of A… Cochrane review What did we learn in 35 years of research on nutrition and supplements…	Nutraceutical	Phase III	Emerging	10	8 trials 10 Cochrane View evidence Registry trials NCT05763940 — Efficacy of OmegaBoost to Increase Omega-3 Levels in Healthy Individuals (UNKNOWN) NA NCT01258335 — Omega-3-fatty Acids on Age-related Macular (COMPLETED) NA NCT02264938 — Drusen Morphology Changes in Nonexudative Age-related Degeneration After Oral Antioxidants Supplementation (COMPLETED) NA NCT00345176 — Age-Related Eye Disease Study 2 (AREDS2) (COMPLETED) PHASE3 NCT03297515 — Therapeutic Potential of Omega-3 Fatty Acids Supplementation in Dry Macular Degeneration and Stargardt Disease (COMPLETED) NA NCT05465252 — Effect of Omega-3 Fatty Acid Supplementation on Dry-AMD Progression (RECRUITING) NA NCT01819415 — Omega-3 Supplementation and Vitreal VEGF Levels in Wet-AMD (COMPLETED) NA NCT01653184 — Effect of Omega-3-fatty Acids on Blood Levels Omega-3 Fatty Acids in Patients With Age-related Macular Degeneration (COMPLETED) NA Published literature Cochrane review Can Omega-3 Fatty Acids Serve as a Preventive Strategy for Age-Related Macular Degeneration? A Systematic Review and Meta-Analysis (The Journal of nutrition, 2026) Cochrane review The Effect of Dietary Supplementations on Delaying the Progression of Age-Related Macular Degeneration: A Systematic Review and Meta-Analysis (Nutrients, 2022) Cochrane review What did we learn in 35 years of research on nutrition and supplements for age-related macular degeneration: a systematic review (Acta ophthalmologica, 2022) Cochrane review What do Cochrane systematic reviews say about interventions for age-related macular degeneration? (Sao Paulo medical journal = Revista paulista de medicina, 2019) Cochrane review Omega 3 fatty acids for preventing or slowing the progression of age-related macular degeneration (The Cochrane database of systematic reviews, 2015) CT.gov search · Cochrane · PubMed		PubChem
Vitamin C Natural product Human Study A combination of nutrients improves age-related macular degeneration. Human Study Antioxidant supplements prevent oxidation of cysteine/cystine redox in… Human Study Supplementation with vitamin C, E, beta-carontene and zinc demonstrates…	Nutraceutical	Approved	Emerging	10	8 trials View evidence Registry trials NCT00055042 — Laser and Antioxidant Treatment of Diabetic Macular Edema (COMPLETED) PHASE1 NCT00000145 — Age-Related Eye Disease Study (AREDS) (COMPLETED) PHASE3 NCT02264938 — Drusen Morphology Changes in Nonexudative Age-related Degeneration After Oral Antioxidants Supplementation (COMPLETED) NA NCT01653184 — Effect of Omega-3-fatty Acids on Blood Levels Omega-3 Fatty Acids in Patients With Age-related Macular Degeneration (COMPLETED) NA NCT00000161 — Randomized Trials of Vitamin Supplements and Eye Disease (UNKNOWN) PHASE3 NCT06391411 — Effect of Micronutrient Supplementation on the Intestinal Microbiota in Patients With Age-related Macular Degeneration - The Gut-Retina-axis Study (COMPLETED) NA NCT00478439 — Investigation of Macular Pigment Augmentation on Dark Adaptation (TERMINATED) PHASE4 NCT00893724 — Supplemental Adjuvants for Intracellular Nutrition and Treatment (UNKNOWN) NA CT.gov search · Cochrane · PubMed		PubChem
Vitamin E Natural product Cochrane review Antioxidant vitamin and mineral supplements for slowing the progression… Cochrane review What did we learn in 35 years of research on nutrition and supplements… Cochrane review Efficacy of different nutrients in age-related macular degeneration: A…	Nutraceutical	Phase III	Emerging	10	8 trials 9 Cochrane 10 Meta-analysis 30 Trial pubs View evidence Registry trials NCT00055042 — Laser and Antioxidant Treatment of Diabetic Macular Edema (COMPLETED) PHASE1 NCT00000145 — Age-Related Eye Disease Study (AREDS) (COMPLETED) PHASE3 NCT02264938 — Drusen Morphology Changes in Nonexudative Age-related Degeneration After Oral Antioxidants Supplementation (COMPLETED) NA NCT00784225 — S0000B: Vitamin E and/or Selenium in Preventing Cataract and Age-Related Macular Degeneration in Men on SELECT SWOG-S0000 (COMPLETED) PHASE3 NCT00021645 — Vitamin E to Treat Uveitis-Associated Macular Edema (COMPLETED) PHASE1 NCT01653184 — Effect of Omega-3-fatty Acids on Blood Levels Omega-3 Fatty Acids in Patients With Age-related Macular Degeneration (COMPLETED) NA NCT00000161 — Randomized Trials of Vitamin Supplements and Eye Disease (UNKNOWN) PHASE3 NCT06391411 — Effect of Micronutrient Supplementation on the Intestinal Microbiota in Patients With Age-related Macular Degeneration - The Gut-Retina-axis Study (COMPLETED) NA Published literature Cochrane review Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration (The Cochrane database of systematic reviews, 2023) Cochrane review What did we learn in 35 years of research on nutrition and supplements for age-related macular degeneration: a systematic review (Acta ophthalmologica, 2022) Cochrane review Efficacy of different nutrients in age-related macular degeneration: A systematic review and network meta-analysis (Seminars in ophthalmology, 2022) Cochrane review The Effectiveness of Pharmacological Agents for the Treatment of Uveitic Macular Edema (UMO): A Systematic Review (Ocular immunology and inflammation, 2019) Cochrane review Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration (The Cochrane database of systematic reviews, 2017) CT.gov search · Cochrane · PubMed		PubChem
Vitamin D3 Natural product Human Study Serum 25(OH)D3 levels may have an impact on the neovascular type of age… Human Study A combination of nutrients improves age-related macular degeneration. Human Study Antioxidant supplements prevent oxidation of cysteine/cystine redox in…	Nutraceutical	Phase III	Emerging	10	8 trials View evidence Registry trials NCT04239625 — Open-Label Extension: Tolerability and Effects of ALK-001 on Stargardt Disease (TEASE) (ACTIVE_NOT_RECRUITING) PHASE2 NCT04482465 — Omega 3 and Vitamin D Dosage in a Population With Moderate to High Risk of AMD (COMPLETED) NA NCT01782352 — Age-related Macular Degeneration (AMD) in the Vitamin D and Omega-3 Trial (VITAL) (UNKNOWN) NA NCT02402660 — Phase 2 Tolerability and Effects of ALK-001 on Stargardt Disease (ENROLLING_BY_INVITATION) PHASE2 NCT01524874 — Comparative Effectiveness of Vitamin D and Repletion Strategies (COMPLETED) NA NCT03845582 — Phase 2/3 Study of ALK-001 in Geographic Atrophy (COMPLETED) PHASE2, PHASE3 NCT02230228 — Phase 1 Safety Study of ALK-001 in Healthy Volunteers (COMPLETED) PHASE1 NCT04177069 — Evaluate the Improving Effects of Visucomplex Plus on Quality of Life in Patients With AMD (UNKNOWN) CT.gov search · Cochrane · PubMed		PubChem
Folate Natural product Clinical trial publication Dietary Nutrient Intake and Progression to Late Age-Related Macular Deg… Clinical trial publication Prospective study of plasma homocysteine, its dietary determinants, and… Clinical trial publication Dietary folate, B vitamins, genetic susceptibility and progression to a…	Nutraceutical	Preclinical	Emerging	10	1 Cochrane 5 Trial pubs View evidence Published literature Clinical trial publication Dietary Nutrient Intake and Progression to Late Age-Related Macular Degeneration in the Age-Related Eye Disease Studies 1 and 2 (Ophthalmology, 2021) Clinical trial publication Prospective study of plasma homocysteine, its dietary determinants, and risk of age-related macular degeneration in men (Ophthalmic epidemiology, 2018) Clinical trial publication Dietary folate, B vitamins, genetic susceptibility and progression to advanced nonexudative age-related macular degeneration with geographic atrophy: a prospective cohort study (The American journal of clinical nutrition, 2016) Clinical trial publication The Association of Dietary Lutein plus Zeaxanthin and B Vitamins with Cataracts in the Age-Related Eye Disease Study: AREDS Report No. 37 (Ophthalmology, 2015) Clinical trial publication Multicenter ophthalmic and nutritional age-related macular degeneration study--part 2: antioxidant intervention and conclusions (Journal of the American Optometric Association, 1996) CT.gov search · Cochrane · PubMed		PubChem
Vitamin B12 Natural product Human Study Supplementation with folic acid, pyridoxine, and cyanocobalamin may red… Human Study A combination of nutrients improves age-related macular degeneration. Human Study Antioxidant supplements prevent oxidation of cysteine/cystine redox in…	Nutraceutical	Preclinical	Emerging	10	1 Meta-analysis 1 Trial pubs View evidence CT.gov search · Cochrane · PubMed		PubChem
Ginger Natural product Animal Study 6-Shogao land dried ginger could be a potential nutraceutical candidate…	Botanical	Preclinical	Emerging	10	No indexed hits View evidence CT.gov search · Cochrane · PubMed		PubChem
Curcumin Natural product Clinical trial publication Oral administration of a curcumin-phospholipid formulation (Meriva®) fo… Human Study Curcuma-based nutritional supplements and risk of age-related macular d… Human In Vitro Turmeric extract and its curcuminoids provided significant protection a…	Food compound	Phase III	Emerging	7	3 trials 1 Trial pubs View evidence Registry trials NCT05062486 — A Study to Evaluate the Safety and Efficacy of RQC for AMD (COMPLETED) PHASE2 NCT06595355 — Efficacy and Safety of Intravitreal Injection of Bevacizumab with and Without Oral Curcumin (RECRUITING) PHASE2, PHASE3 NCT04590196 — Effect of Oral Curcumin Supplementation in Dry Age-related Macular Degeneration (AMD) Patients (COMPLETED) EARLY_PHASE1 Published literature Clinical trial publication Oral administration of a curcumin-phospholipid formulation (Meriva®) for treatment of chronic diabetic macular edema: a pilot study (European review for medical and pharmacological sciences, 2018) CT.gov search · Cochrane · PubMed		PubChem
Saffron Natural product Clinical trial publication Beneficial Effects of Micronutrient Supplementation in Restoring the Al… Clinical trial publication Saffron therapy for the ongoing treatment of age-related macular degene… Clinical trial publication An Open-Label Pilot Study on Macumax Supplementation for Dry-Type Age-R…	Botanical	Phase II	Emerging	7	3 trials 8 Trial pubs View evidence Registry trials NCT00951288 — Effect of Saffron Supplementation on Macular Cone-mediated Function in Age-related Macular Degeneration (UNKNOWN) PHASE1, PHASE2 NCT01278277 — Saffron Supplementation in Stargardt's Disease (UNKNOWN) PHASE1, PHASE2 NCT06391411 — Effect of Micronutrient Supplementation on the Intestinal Microbiota in Patients With Age-related Macular Degeneration - The Gut-Retina-axis Study (COMPLETED) NA Published literature Clinical trial publication Beneficial Effects of Micronutrient Supplementation in Restoring the Altered Microbiota and Gut-Retina Axis in Patients with Neovascular Age-Related Macular Degeneration-A Randomized Clinical Trial (Nutrients, 2024) Clinical trial publication Saffron therapy for the ongoing treatment of age-related macular degeneration (BMJ open ophthalmology, 2024) Clinical trial publication An Open-Label Pilot Study on Macumax Supplementation for Dry-Type Age-Related Macular Degeneration (Journal of medicinal food, 2021) Clinical trial publication Antioxidant Saffron and Central Retinal Function in ABCA4-Related Stargardt Macular Dystrophy (Nutrients, 2019) Clinical trial publication Saffron therapy for the treatment of mild/moderate age-related macular degeneration: a randomised clinical trial (Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2019) CT.gov search · Cochrane · PubMed		PubChem
Resveratrol Natural product Human Study A diet low in trans-unsaturated fat and rich in omega-3 fatty acids and… Review "Chromotherapy of macular degeneration with transitions lenses and… Review Health benefits of polyphenols and carotenoids in age-related eye disea…	Food compound	Phase II	Emerging	7	3 trials 2 Trial pubs View evidence Registry trials NCT05062486 — A Study to Evaluate the Safety and Efficacy of RQC for AMD (COMPLETED) PHASE2 NCT04756310 — Study of Nutritional Supplementation in Patients With Unilateral Wet AMD (COMPLETED) NA NCT02625376 — Resveratrol for Exudative Age-Related Macular Degeneration (TERMINATED) NA CT.gov search · Cochrane · PubMed		PubChem
Melatonin Natural product Human Study Effects of Macuprev® supplementation in age-related macular degeneratio… Human Study Goji berry supplementation may be of therapeutic value in macular degen… Human Study Lutein supplementation improves visual function in those with age-relat…	Nutraceutical	Preclinical	Emerging	7	1 trials 1 Meta-analysis View evidence Registry trials NCT00444249 — Influence of Blue Light Filtering Intraocular Lenses on Daytime Levels of Melatonin (TERMINATED) NA CT.gov search · Cochrane · PubMed		PubChem
Sulforaphane Natural product Reactive oxygen species and oxidative stress in ocular disease: from mo… Sulforaphane and ophthalmic diseases Vitamin D and Sulforaphane Decrease Inflammatory Oxidative Stress and R…	Food compound	Preclinical	Emerging	7	No indexed hits View evidence CT.gov search · Cochrane · PubMed		PubChem
Spirulina Natural product Animal Study, In Vitro Study Protective effects of Spirulina maxima against blue light-induced retin… Animal Study Spirulina ingestion protected retinal photoreceptors from photostress i…	Nutraceutical	Preclinical	Emerging	7	No indexed hits View evidence CT.gov search · Cochrane · PubMed		—
Cordyceps Natural product Animal Study C. militaris extract has the potential to prevent or treat light-induce… In Vitro Study Cordyceps militaris carotenoids protect human retinal endothelial cells…	Mushroom	Preclinical	Emerging	7	No indexed hits View evidence CT.gov search · Cochrane · PubMed		—
Black Seed Oil Natural product	Botanical	Preclinical	Emerging	7	No indexed hits View evidence CT.gov search · Cochrane · PubMed		PubChem
Coenzyme Q10 Natural product Human Study A combination of acetyl-l-carnitine, n-3 fatty acids and coenzyme q10 i…	Nutraceutical	Preclinical	Emerging	7	—		PubChem
Alpha-Lipoic Acid Natural product Human Study Alpha-lipoic acid treatment improves vision-related quality of life in…	Nutraceutical	Preclinical	Emerging	7	—		PubChem
Reishi Natural product Human Study Effects of Macuprev® supplementation in age-related macular degeneratio…	Mushroom	Preclinical	Emerging	7	—		—
Glucosamine Natural product Human Study Glucosamine treatment can decrease the risk of developing dry type age-…	Nutraceutical	Preclinical	Emerging	7	—		PubChem
Egcg Natural product Human Study Moderate consumption of eggs significantly reduces the risk of developi… Review "Chromotherapy of macular degeneration with transitions lenses and…	Food compound	Preclinical	Emerging	7	—		PubChem
Berberine Natural product Review Berberine and Curcumin could be useful against ocular disorders.	Botanical	Preclinical	Emerging	7	—		PubChem
Quercetin Natural product Review Health benefits of polyphenols and carotenoids in age-related eye disea…	Food compound	Preclinical	Emerging	7	—		PubChem
Ginkgo Biloba Natural product Human Study Ginkgo biloba shows promise in the treatment of senile macular degenera… Review G. biloba extracts might be a good option to improve certain neurodegen… In Vitro Study Ginkgo biloba extracts (GBE) protect human RPE cells from t-BHP-induced…	Botanical	Preclinical	Emerging	2	—		—
Tamsulosin Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Terazosin Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Yohimbine Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Indoramin Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Phentolamine Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Prazosin Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Imatinib Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Clonidine Natural product Guanabenz and Clonidine, α2-Adrenergic Receptor Agonists, Inhibit Choro… Influx Transport of Cationic Drug at the Blood-Retinal Barrier: Impact…	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Apraclonidine Natural product Drugs for common eye disorders	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Doxazosin Natural product Antiangiogenic Effects of Doxazosin on Experimental Choroidal Neovascul…	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Mianserin Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Akuammigine Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Rauwolscine Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Corynantheine Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Oxymetazoline Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Genistein Natural product Natural product inhibitors of ocular angiogenesis Genistein attenuates choroidal neovascularization VEGF modulation of retinal pigment epithelium resistance	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Atipamezole Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Vancomycin Natural product Streptococcus salivarius endophthalmitis and corneal ring infiltrate af… A second occurrence of intravitreal injection-associated endophthalmiti… A NOVEL CASE OF ENDOPHTHALMITIS SECONDARY TO PAENIBACILLUS YONGINENSIS…	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Desglymidodrine Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Phenylpropanolamine Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Dexniguldipine Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Niguldipine Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Alprenolol Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Betaxolol Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Carteolol Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Propranolol Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Tak-901 Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Nintedanib Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Tivozanib Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Tak-593 Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Saracatinib Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Danusertib Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Axitinib Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Erlotinib Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Tg100-801 Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Adavosertib Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
At-9283 Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Lenvatinib Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Aee-788 Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Masitinib Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Ibrutinib Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Fedratinib Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Pf-03758309 Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Acalabrutinib Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Carprofen Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Oxaprozin Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Raloxifene Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
2-arachidonoylglycerol Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
N-Isopropylpalmitamide Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
(E)-8-methyl-N-vanillyl-non-6-enamide Natural product	Food compound	Preclinical	Emerging	0	—	ClinicalTrials.gov	PubChem
2-hydroxybenzenecarbohydroxamic Acid Natural product	Food compound	Preclinical	Emerging	0	—	ClinicalTrials.gov	PubChem
Astaxanthin Natural product Human Study A combination of nutrients improves age-related macular degeneration. Animal Study Astaxanthin protects human ARPE-19 retinal pigment epithelium cells fro… Animal Study Astaxanthin protects retinal cells against oxidative damage.	Food compound	Preclinical	Emerging	0	—		PubChem

Alterations and therapeutics are aggregated from public databases (Open Targets, HPO, ChEMBL, DGIdb, and others). Natural agents are candidates from OSMF narrative reviews on opensourcemed.info/chronic-disease.html — not approved treatments. This page is for research orientation only — not medical advice.